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Summary 
 
In preparation for a legal implementation of EU-regulation 1829/2003, the Norwegian Scientific 
Committee for Food Safety (VKM) has been requested by the Norwegian Environment Agency 
(former Norwegian Directorate for Nature Management) and the Norwegian Food Safety Authority 
(NFSA) to conduct final food/feed and environmental risk assessments for all genetically modified 
organisms (GMOs) and products containing or consisting of GMOs that are authorized in the 
European Union under Directive 2001/18/EC or Regulation 1829/2003/EC. The request covers 
scope(s) relevant to the Gene Technology Act. The request does not cover GMOs that VKM already 
has conducted its final risk assessments on. However, the Agency and NFSA requests VKM to 
consider whether updates or other changes to earlier submitted assessments are necessary.  
 
The insect-resistant and herbicide-tolerant genetically modified maize Bt11 from Syngenta Seeds 
(Unique Idientifier SYN-BT Ø11-1) is approved under Regulation (EC) No 1829/2003 for food and 
feed uses, import and processing (Commission Decision 2010/419/EC).  
 
Genetically modified maize Bt11 has previously been risk assessed by the VKM Panel on Genetically 
Modified Organisms (GMO) as sweet maize in 2005 (Notification xx) and fodder/field maize in  2007 
(Notification C/F/96/05.10) (VKM 2005, VKM 2007). Bt11 has also been evaluated by the VKM 
GMO Panel as a component of several stacked GM maize events (VKM 2008, VKM 2009a,b,c,d,e 
VKM 2012a,b, 2013a,b,c).  
 
The food/feed and environmental risk assessment of the maize Bt11 is based on information provided 
by the applicant in the application EFSA/GMO/RX/Bt11, and scientific comments from EFSA and 
other member states made available on the EFSA website GMO Extranet. The risk assessment also 
considered other peer-reviewed scientific literature as relevant.   
 
The VKM GMO Panel has evaluated Bt11 with reference to its intended uses in the European 
Economic Area (EEA), and according to the principles described in the Norwegian Food Act, the 
Norwegian Gene Technology Act and regulations relating to impact assessment pursuant to the Gene 
Technology Act, Directive 2001/18/EC on the deliberate release into the environment of genetically 
modified organisms, and Regulation (EC) No 1829/2003 on genetically modified food and feed. The 
Norwegian Scientific Committee for Food Safety has also decided to take account of the appropriate 
principles described in the EFSA guidelines for the risk assessment of GM plants and derived food and 
feed (EFSA 2011a), the environmental risk assessment of GM plants (EFSA 2010), selection of 
comparators for the risk assessment of GM plants (EFSA 2011b) and for the post-market 
environmental monitoring of GM plants (EFSA 2011c).  
 
The scientific risk assessment of maize Bt11 include molecular characterisation of the inserted DNA 
and expression of novel proteins, comparative assessment of agronomic and phenotypic 
characteristics, nutritional assessments, toxicology and allergenicity, unintended effects on plant 
fitness, potential for gene transfer, interactions between the GM plant and target and non-target 
organisms and effects on biogeochemical processes.  
 
It is emphasized that the VKM mandate does not include assessments of contribution to sustainable 
development, societal utility and ethical considerations, according to the Norwegian Gene Technology 
Act and Regulations relating to impact assessment pursuant to the Gene Technology Act. These 
considerations are therefore not part of the risk assessment provided by the VKM Panel on Genetically 
Modified Organisms.  
 
Molecular characterisation  
The molecular characterisation data indicate that a single copy of the transgenic insert with the cry1Ab 
and pat genes is integrated  in the nuclear genome of maize Bt11, and that it is inherited as a dominant, 
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single locus trait. Appropriate analyses of the integration site, inserted DNA sequence, flanking 
regions, and bioinformatics have been performed. The VKM GMO Panel considers the molecular 
characterisation of maize Bt11 as adequate. 
 
Comparative assessment 
Comparative analyses of data from field trials located at representative sites and environments in 
North America and Europe indicate that maize Bt11 is compositionally equivalent to its conventional 
counterpart, with the exception of the herbicide tolerance and insect resistance traits, conferred by the 
expression of the Cry1Ab and PAT proteins. However, data on the amino acid tryptophan, is only 
given in one out of six studies. Based on current knowledge, the VKM GMO panel concludes that 
maize Bt11 is compositionally equivalent to conventional maize. 
 
The data provided by the applicant are not sufficient to show that Bt11 maize is phenotypically and 
agronomically equivalent to conventional near-isogenic maize lines. The agronomic assessment data 
are provided from one growing season in the North America and one growing season in France. This 
is not considered to be sufficient for representative testing of agricultural environments. 
 
Food and feed risk assessment 
Whole food feeding studies have not indicated any adverse health effects of maize Bt11. These studies 
also indicate that maize Bt11 is nutritionally equivalent to conventional maize. The Cry1Ab and PAT 
proteins do not show sequence resemblance to other known toxins or IgE allergens, nor have they 
been reported to cause IgE mediated allergic reactions. Some studies have however indicated a 
potential role of Cry-proteins as adjuvants in allergic reactions. 
 
Based on current knowledge, the VKM GMO Panel concludes that maize Bt11 is nutritionally 
equivalent to conventional maize varieties. It is unlikely that the Cry1Ab and PAT proteins will 
introduce a toxic or allergenic potential in food or feed based on maize Bt11 compared to conventional 
maize. 
 
Environmental risk assessment 
The scope of the application EFSA/GMO/RX/Bt11 includes import and processing of maize stack 
Bt11 for food and feed uses. Considering the intended uses of maize Bt11, excluding cultivation, the 
environmental risk assessment is concerned with accifieldal release into the environment of viable 
grains during transportation and processing, and indirect exposure, mainly through manure and faeces 
from animals fed grains from maize Bt11.  
 
Maize Bt11 has no altered survival, multiplication or dissemination characteristics, and there are no 
indications of an increased likelihood of spread and establishment of feral maize plants in the case of 
accifieldal release into the environment of seeds from maize Bt11. Maize is the only representative of 
the genus Zea in Europe, and there are no cross-compatible wild or weedy relatives outside 
cultivation. The VKM GMO Panel considers the risk of gene flow from occasional feral GM maize 
plants to conventional maize varieties to be negligible in Norway. Considering the intended use as 
food and feed, interactions with the biotic and abiotic environment are not considered by the GMO 
Panel to be an issue. 
 
Overall conclusion 
Based on current knowledge, the VKM GMO Panel concludes that maize Bt11 is nutritionally 
equivalent to conventional maize varieties. It is unlikely that the Cry1Ab and PAT proteins will 
introduce a toxic or allergenic potential in food or feed derived from maize Bt11 compared to 
conventional maize.  
 
The VKM GMO Panel likewise concludes that maize Bt11, based on current knowledge, is 
comparable to conventional maize varieties concerning environmental risk in Norway with the 
intended usage. 
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I forbindelse med forberedelse til implementering av EU-forordning 1829/2003 i norsk rett, er 
Vitenskapskomiteen for mattrygghet (VKM) bedt av Miljødirektoratet (tidligere Direktoratet for 
naturforvalting (DN)) og Mattilsynet om å utarbeide endelige helse- og miljørisikovurderinger av alle 
genmodifiserte organismer (GMOer) og avledete produkter som inneholder eller består av GMOer 
som er godkjent under forordning 1829/2003 eller direktiv 2001/18, og som er godkjent for ett eller 
flere bruksområder som omfattes av genteknologiloven. Miljødirektoratet og Mattilsynet har bedt 
VKM om endelige risikovurderinger for de EU-godkjente søknader hvor VKM ikke har avgitt 
endelige risikovurderinger. I tillegg er VKM bedt om å vurdere hvorvidt det er nødvendig med 
oppdatering eller annen endring av de endelige helse- og miljørisikovurderingene som VKM tidligere 
har levert. 
 
Den insektsresistente og herbicidtolerante maislinjen Bt11 (unik kode SYN-BT Ø11-1) fra Syngenta 
Seeds er godkjent til import, videreforedling og til bruk som mat og fôr under EU-forordning 
1829/2003 (søknad EFSA/GMO/RX/Bt11, Kommisjonsbeslutning 2010/419/EU).   
 
Maislinjen Bt11 har tidligere vært vurdert av VKMs faggruppe for genmodifiserte organismer med 
hensyn på mulig helserisiko. Maislinjen ble risikovurdert som sukkermais i 2005 (Notifisering xx) 
(VKM 2005) og som fôrmais i 2007 (Notifisering C/F/96/05.10) (VKM 2007). Bt11 også tidligere 
risikovurdert av VKM i en rekke hybrider, der Bt11 inngår som en av foreldrelinjene (VKM 2008, 
VKM 2009a,b,c,d,e VKM 2012a,b, 2013a,b,c).  
 
Risikovurderingen av den genmodifiserte maislinjen er basert på uavhengige vitenskapelige 
publikasjoner og dokumentasjon som er gjort tilgjengelig på EFSAs nettside EFSA GMO Extranet. 
Vurderingen er gjort i henhold til tiltenkt bruk i EU/EØS-området, og i overensstemmelse med 
miljøkravene i genteknologiloven med forskrifter, først og fremst forskrift om konsekvensutredning 
etter genteknologiloven. Videre er kravene i EU-forordning 1829/2003/EF, utsettingsdirektiv 
2001/18/EF (vedlegg 2,3 og 3B) og veiledende notat til Annex II (2002/623/EF), samt prinsippene i 
EFSAs retningslinjer for risikovurdering av genmodifiserte planter og avledete næringsmidler (EFSA 
2006, 2010, 2011a,b,c) lagt til grunn for vurderingen.  
 
Den vitenskapelige vurderingen omfatter transformeringsprosess og vektorkonstruksjon, 
karakterisering og nedarving av genkonstruksjonen, komparativ analyse av ernæringsmessig kvalitet, 
mineraler, kritiske toksiner, metabolitter, antinæringsstoffer, allergener og nye proteiner. Videre er 
agronomiske egenskaper, potensiale for utilsiktede effekter på fitness, genoverføring og effekter på 
ikke-målorganismer vurdert. 
 
Det presiseres at VKMs mandat ikke omfatter vurderinger av etikk, bærekraft og samfunnsnytte, i 
henhold til kravene i den norske genteknologiloven og dens konsekvensutredningsforskrift. Disse 
aspektene blir derfor ikke vurdert av VKMs faggruppe for genmodifiserte organismer. 
 
Molekylær karakterisering 
Data fra den molekylære karakteriseringen indikerer at det kun er integrert ett eksemplar av 
ekspresjonskassetten med Cry1Ab og pat i genomet til mais Bt11, og at genene og egenskapene er 
dominant og stabilt nedarvet. Bioinformatikk- og sekvensanalyser er utført av integreringssete i 
plantens genom, og innsatt og flankerende DNA. VKMs faggruppe for genmodifiserte organismer 
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Data fra feltforsøk i Nord-Amerika og Europa indikerer, med unntak av insektsresistens og 
herbicidtoleranse, ekvivalens mellom genmodifisert mais Bt11 og korresponderende, nær-isogene 
kontrollinjer med hensyn på ernæringsmessige karakterer. Faggruppen peker imidlertid på at  
aminosyren tryptofan kun er analysert i ett av de seks studiene som er vedlagt søkers dokumentasjon.  
Faggruppen vurderer også at søkers dokumentasjon knyttet til fenotypiske og agronomiske karakterer 




Fôringsstudier utført på rotter og broiler har ikke indikert helseskadelige effekter av mais Bt11. 
Cry1Ab– proteinet viser ingen likhet til kjente toksiner eller allergener, og er heller ikke rapportert å 
ha forårsaket IgE-medierte allergiske reaksjoner. Det er heller ikke dokumentert at noen av proteinene 
kan utløse IgE-medierte allergiske reaksjoner. Enkelte studier har derimot indikert at noen typer Cry-
proteiner potensielt kan forsterke andre allergiske reaksjoner (virke som adjuvans). 
 
Ut i fra dagens kunnskap konkluderer VKMs faggruppe for GMO at mais Bt11 er næringsmessig 
vesentlig lik konvensjonell mais, og at det er lite trolig at de nye proteinene vil introdusere et toksisk 




Søknaden gjelder godkjenning av maishybrid Bt11 for import, prosessering og til bruk i næringsmidler 
og fôrvarer, og omfatter ikke dyrking. Med bakgrunn i tiltenkt bruksområde er miljørisikovurderingen 
avgrenset til mulige effekter av utilsiktet frøspredning i forbindelse med transport og prosessering, 
samt indirekte eksponering gjennom gjødsel fra husdyr fôret med genmodifisert mais.  
 
Det er ingen indikasjoner på økt sannsynlighet for spredning, etablering og invasjon av maislinjen i 
naturlige habitater eller andre arealer utenfor jordbruksområder som resultat av frøspill i forbindelse 
med transport og prosessering. Risiko for utkryssing med dyrkede sorter vurderes av GMO panelet til 
å være ubetydelig. Ved foreskreven bruk av maislinjen Bt11 antas det ikke å være risiko for utilsiktede 
effekter på målorganismer, ikke-målorganismer eller på abiotisk miljø i Norge. 
 
Samlet vurdering  
VKMs faggruppe for GMO har ikke ifieldifisert toksiske eller endrede ernæringsmessige egenskaper 
til mais Bt11 eller prosesserte produkter sammenliknet med konvensjonell mais. Basert på dagens 
kunnskap er det også lite trolig at Cry1Ab1- og PAT- proteinene vil øke det allergene potensialet til 
mat og fôr produsert fra mais Bt11 sammenliknet med konvensjonelle maissorter. Faggruppen finner 
at maislinje Bt11, ut fra dagens kunnskap og omsøkt bruk, er sammenlignbar med konvensjonell mais 
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Abbreviations and explanations 
ALS Acetolactate synthase, an enzyme that catalyses the first step in the 
synthesis of the branched-chain amino acids, valine, leucine, and 
isoleucine 
AMPA Aminomethylphosphonic acid, one of the primary degradation products of 
glyphosate 
ARMG Antibiotic resistance marker gene  
BC Backcross. Backcross breeding in maize is extensively used to move a 
single trait of interest (e.g. disease resistance gene) from a donor line into 
the genome of a preferred or “elite” line without losing any part of the 
preferred lines existing genome. The plant with the gene of interest is the 
donor parent, while the elite line is the recurrent parent. BC1, BC2 etc. 
designates the backcross generation number. 
BLAST Basic Local Alignment Search Tool. Software that is used to compare 
nucleotide (BLASTn) or protein (BLASTp) sequences to sequence 
databases and calculate the statistical significance of matches, or to find 
potential translations of an unknown nucleotide sequence (BLASTx). 
BLAST can be used to understand functional and evolutionary 
relationships between sequences and help identify members of gene 
families.  
bp Basepair 
Bt  Bacillus thuringiensis 
CaMV Cauliflower mosaic virus 
Codex Set by The Codex Alimentarius Commission (CAC), an intergovernmental 
body to implement the Joint FAO/WHO Food Standards Programme. Its 
principle objective is to protect the health of consumers and to facilitate 
the trade of food by setting international standards on foods (i.e. Codex 
Standards). 
Cry Any of several proteins that comprise the crystal found in spores of 
Bacillus thuringiensis. Activated by enzymes in the insects midgut, these 
proteins attack the cells lining the gut, and subsequently kill the insect. 
Cry1Ab Cry1 class crystal protein from Bacillus thuringiensis subsp. 
kurstaki.  Provide protection against certain lepidopteran target pests, such 
as the European maize borer (Ostrinia nubilalis), and species belonging to 
the genus Sesamia 
CTP Chloroplast transit peptide 
DAP  Days after planting 
DNA Deoxyribonucleic acid 
DT50 Time to 50% dissipation of a protein in soil 
DT90 Time to 90% dissipation of a protein in soil 
dw Dry weight 
dwt Dry weight tissue 
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EC European Commission 
ECB European corn borer, Ostrinia nubilalis 
EFSA European Food Safety Authority 
ELISA Enzyme-linked immunosorbent assay 
ERA Environmental risk assessment 
E-score Expectation score 
EU European Union 
fa Fatty acid 
FAO Food and Agriculture Organisation 
FIFRA US EPA Federal Insecticide, Fungicide and Rodenticide Act 
Fitness Describes an individual's ability to reproduce successfully relative to that 
of other members of its population. 
fw Fresh weight 
fwt Fresh weight tissue 
GAT Glyphosate N-acetyltransferase 
GLP Good Laboratory Practice 
Glufosinate-
ammonium 
Broad-spectrum  systemic herbicide 
Glyphosate Broad-spectrum  systemic herbicide 
GM Genetically Modified 
GMO Genetically Modified Organism 
GMP Genetically Modified Plant 
H Hybrid 
ha Hectare 
ILSI International Life Sciences Institute 
IPM Integrated Pest Management 
IRM Insect Resistance Management 
Locus The position/area that a given gene occupies on a chromosome 
LOD Limit of detection 
LOQ Limit of quantification 
MALDI-TOF Matrix-Assisted Laser Desorption/Ionization-Time Of Flight. A mass 
spectrometry method used for detection and characterisation of 
biomolecules, such as proteins, peptides, oligosaccharides and 
oligonucleotides, with molecular masses between 400 and 350,000 Da. 
MCB Mediterranean corn borer, Sesamia nonagrioides 
mEPSPS Modified 5-enolpyruvylshikimate-3-phosphate synthase 
mRNA Messenger RNA 
MT Norwegian Food Safety Authority (Mattilsynet) 
NDF Neutral detergent fibre, measure of fibre used for animal feed analysis. 
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NDF measures most of the structural components in plant cells (i.e. lignin, 
hemicellulose and cellulose), but not pectin. 
Northern blot Northern blot is a technique used to study gene expression by detection of 
RNA or mRNA separated in a gel according to size.  
NTO  Non-target organism 
Nicosulfuron Herbicide for maize that inhibits the activity of acetolactate synthase 
Near-isogenic lines  Term used in genetics/plant breeding, and defined genetic lines that are 
identical except for differences at a few specific locations or genetic loci. 
OECD Organisation for Economic Co-operation and Development 
ORF Open Reading Frame, in molecular genetics defined as a reading frame 
that can code for amino acids between two stop codons (without stop 
codons). 
OSL Over season leaf 
OSR Over season root 
OSWP Over season whole plant 
pat Phosphinothricin-Acetyl-Transferase gene 
PAT Phosphinothricin-Acetyl-Transferase protein 
PCR Polymerase chain reaction, a technique to amplify DNA by copying it 
PMI Phosphomannose Isomerase enzyme. Metabolizes mannose and allows 
positive selection for recovery of transformed plants. 
R0 First transformed generation, parent 
Rimsulferon Herbicide, inhibits acetolactate synthase 
RNA Ribonucleic acid 
RP Recurrent parent 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis. Technique 
to separate proteins according to their approximate size 
SAS Statistical Analysis System 
SD Standard deviation 
Southern blot Method used for transfer of electrophoresis-separated DNA fragments to a 
filter membrane and possible subsequent fragment detection by probe 
hybridisation 
T-DNA Transfer DNA, the transferred DNA of the tumour-inducing (Ti) plasmid 
of some species of bacteria such as Agrobacterium tumefaciens and A. 
rhizogenes, into plant's nuclear genome. The T-DNA is bordered by 25-
base-pair repeats on each end. Transfer is initiated at the left border and 
terminated at the right border and requires the vir genes of the Ti plasmid. 
TI Trait integrated 
TMDI Theoretical Maximum Daily Intake 
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Maize growth stages Vegetative 
 VE: emergence from soil surface 
 V1: collar of the first leaf is visible 
 V2: collar of the second leaf is visible  
 Vn: collar of the leaf number 'n' is visible  
 VT: last branch of the tassel is completely visible 
 Reproductive 
 R0: Anthesis or male flowering. Pollen shed begins 
 R1: Silks are visible 
 R2: Blister stage. The kernels are filled with a clear nourishing endosperm 
fluid and the embryo can be seen  
 R3: Milk stage. The kernels endosperm is milky white.  
 R4: Dough stage. The kernels endosperm has developed to a white paste  
 R5: Dent stage. If the genotype is a dent type, the grains are dented 
 R6: Physiological maturity 
 Western blot Technique used to transfer proteins separated by gel electrophoresis by 3-
D structure or denatured proteins by the length of the polypeptide to a 
membrane, where they might be identified by antibody labelling. 
WHO World Health Organisation 
ZM Zea maize L. 
ZM-HRA A modified version of the native acetolactate synthase protein from maize. 
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On 17 April 2007, Syngenta Seeds, submitted to the European Commission an application, in 
accordance with Articles 5, 11, 17 and 23 of Regulation (EC) No 1829/2003, for renewal of the 
authorisation for continued marketing of existing foods and food ingredients produced from Bt11 
maize (including food additives), and renewal of the authorisation for continued marketing of existing 
feed containing, consisting of or produced from Bt11 maize (including feed additives and feed 
materials) and products other than food and feed containing and consisting of Bt11 maize with the 
exception of cultivation which were previously notified in accordance with Article 8(1)(a)(b) and 
Article 20(1)(a)(b) of that Regulation. The application also covers the renewal of the authorisation for 
the placing on the market of foods and food ingredients which are authorised under Commission 
Decision 2004/657/EC of 19 May 2004 authorising the placing on the market of sweet maize from 
genetically modified maize line Bt11 as a novel food or novel food ingredient under Regulation (EC) 
No 258/97. Within its application, Syngenta Seeds also requested the authorisation of foods and food 
ingredients containing or consisting of Bt11 field maize which were never authorised in the EU.  
 
In 2009, the EFSA GMO Panel delivered a scientific opinion for the continued marketing of existing 
products produced from maize Bt11 for import, processing for food & feed uses, but not for 
cultivation (EFSA 2009a). EFSA  concluded that the new information provided in the application and 
the review of the literature that has been published since the previous scientific opinion on Bt11 maize 
by EFSA does not require changes and confirmed the previous conclusion that Bt11 maize is as safe as 
its non-genetically modified counterpart and that it is unlikely to have an adverse effect on human and 
animal health or the environment in the context of its proposed uses which also applies to the products 
which are subject of the application. 
 
On 29 July 2010 the European Commission granted a renewing of the authorisation for continued 
marketing of products containing, consisting of, or produced from genetically modified maize Bt11, 
authorising foods and food ingredients containing or consisting of field maize Bt11 pursuant to 
Regulation (EC) No 1829/2003 (Commission Decision 2010/419/EU).  
 
The authorisation covers: 
• Foods and food ingredients containing, consisting of or produced from SYN-BTØ11-1 maize 
• Feed containing, consisting of, or produced from SYN- BTØ11-1 maize 
• Products other than food and feed containing or consisting of SYN-BTØ11-1 maize for the 
same uses as any other maize with the exception of cultivation.  
 
Notification C/F/96/05.10 
On 16 June 2003, the European Commission received from the Competent Authority of France a 
notification (reference C/F/96/02.10) under Part C of Directive 2001/18/EC, for authorisation of the 
insect-resistant and herbicide tolerant genetically modified maize Bt11 for cultivation, feed use and 
industrial processing.  
 
On 20 April 2005, the EFSA GMO Panel issued a scientific opinion on the notification (EFSA 2005), 
and concluded that there was no evidence indicating that placing maize Bt11 on the market is likely to 
cause adverse effects on human or animal health or the environment in the context of its proposed 
uses. At the time, the EFSA GMO Panel also recommended that maize Bt11 cultivation should be 
accompanied by appropriate risk management strategies to delay the potential evolution of resistance 
to the Cry1Ab protein in target insects and to minimise exposure of non-target Lepidoptera (EFSA 
2005).  
 
In both 2006 and 2008, the European Commission requested the EFSA GMO Panel to consider 
whether new evidence published in the scientific literature required a revision of the conclusions of its  
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2005 Scientific Opinion on maize Bt11 (EFSA 2005). Following these requests, the EFSA GMO Panel 
evaluated the available new scientific information, and found no new evidence for adverse effects 
caused by the cultivation of maize Bt11 (EFSA 2006, 2008). Therefore, the EFSA GMO Panel  
concluded that no new scientific information had been made available that would invalidate its 
previous risk assessment conclusions.  
 
On 8 December 2010, the European Commission requested the EFSA GMO Panel to consider whether  
new scientific elements might require a revision of the conclusions of its previous Scientific Opinion 
on maize Bt11 in particular in the light of the mathematical model applied to the risk assessment of the  
insect resistant maize 1507. On 30 November 2011, the EFSA GMO Panel adopted a Statement 
supplementing the environmental risk assessment conclusions and risk management recommendations 
on maize Bt11 cultivation. In its Statement, the EFSA GMO Panel concluded that: “subject to 
appropriate management measures, maize Bt11 cultivation is unlikely to raise additional safety 
concerns for the environment compared to conventional maize” (EFSA 2011a).  
 
The EFSA GMO Panel further supplemented its previous risk management recommendations on 
maize Bt11 for cultivation by reapplying the mathematical model developed by Perry et al. (2010, 
2011, 2012), in order to consider additional hypothetical agricultural conditions, and to provide 
additional information on the factors affecting the insect resistance management plan (EFSA 2012a).  
Following a request from the European Commission, the EFSA GMO Panel compiled its previous risk 
assessment conclusions and risk management recommendations on maize Bt11, and considered their  
validity in the light of new relevant scientific publications published from 2005 onwards.  A scientific 
opinion updating the risk assessment conclusions and risk management recommendations on Bt11 was 
published 11 December 2012 (EFSA 2012b). 
 
Norway 
Genetically modified maize Bt11 has previously been risk assessed by the VKM Panel on Genetically 
Modified Organisms (GMO) as sweet maize in 2005 and field maize in 2007 (Notification 
C/F/96/05.10) (VKM 2005, 2007). Due to the publication of new scientific literature and updated 
guidelines for risk assessment of genetically modified plants, the VKM GMO Panel has decided to 
deliver an updated food/feed and environmental risk assessment of Bt11. Bt11 has also been evaluated 
by the VKM GMO Panel as a component of several stacked GM maize events (VKM 2008, VKM 
2009a,b,c,d,e VKM 2012a,b, 2013a,b,c).  
 
Through the Agreement of the European Economic Area (EEA), Norway is obliged to implement the 
EU regulations on GM food and feed (regulations 1829/2003, 1830/2003 et al). Until implementation 
of these regulations, Norway has a national legislation concerning processed GM food and feed 
products that are harmonised with the EU legislation. These national regulations entered into force 15 
September 2005. For genetically modified feed and some categories of genetically modified food, no 
requirements of authorisation were required before this date. Such products that were lawfully placed 
on the Norwegian marked before the GM regulations entered into force, the so-called existing 
products, could be sold in a transitional period of three years when specific notifications were sent to 
the Norwegian Food Safety Authority. Within three years after 15. September 2005, applications for 
authorisation should be sent to the Authority before further marketing. Four fish feed producing 
companies have once a year since 2008, applied for an exemption of the authorisation requirements of 
19 existing products, including maize Bt11. These 19 GM events are all authorised in the EU, and the 
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Terms of reference 
 
 
The Norwegian Environment Agency (former Norwegian Directorate for Nature Management) has the 
overall responsibility for processing applications for the deliberate release of genetically modified 
organisms (GMOs). This entails inter alia coordinating the approval process, and to make a holistic 
assessment and recommendation to the Ministry of the Environment regarding the final authorization 
process in Norway. The Directorate is responsible for assessing environmental risks on the deliberate 
release of GMOs, and to assess the product's impact on sustainability, benefit to society and ethics 
under the Gene Technology Act. 
 
The Norwegian Food Safety Authority (NFSA) is responsible for assessing risks to human and animal 
health on deliberate release of GMOs pursuant to the Gene Technology Act and the Food Safety Act. 
In addition, the NFSA administers the legislation for processed products derived from GMO and the 
impact assessment on Norwegian agriculture according to sector legislation. 
 
 
The Norwegian Environment Agency 
 
In preparation for a legal implementation of EU-regulation 1829/2003, the Norwegian Environment 
Agency, by letter dated 13 June 2012 (ref. 2008/4367/ART-BI-BRH), requests the Norwegian 
Scientific Committee for Food Safety, to conduct final environmental risk assessments for all 
genetically modified organisms (GMOs) and products containing or consisting of GMOs that are 
authorized in the European Union under Directive 2001/18/EC or Regulation 1829/2003/EC. The 
request covers scope(s) relevant to the Gene Technology Act. 
 
The request does not cover GMOs that the Committee already has conducted its final risk assessments 
on. However, the Norwegian Environment Agency requests the Committee to consider whether 
updates or other changes to earlier submitted assessments are necessary. 
 
The basis for evaluating the applicants’ environmental risk assessments is embodied in the Act 
Relating to the Production and Use of Genetically Modified Organisms etc. (the Norwegian Gene 
Technology Act), Regulations relating to impact assessment pursuant to the Gene Technology Act, the 
Directive 2001/18/EC on the deliberate release of genetically modified organisms into the 
environment, Guidance note in Annex II of the Directive 2001/18 (2002/623/EC) and the Regulation 
1829/2003/EC. In addition, the EFSA guidance documents on risk assessment of genetically modified 
plants and food and feed from the GM plants (EFSA 2010, 2011a), and OECD guidelines will be 
useful tools in the preparation of the Norwegian risk assessments. 
 
The risk assessments’ primary geographical focus should be Norway, and the risk assessments should 
include the potential environmental risks of the product(s) related to any changes in agricultural 
practices. The assignment covers assessment of direct environmental impact of the intended use of 
pesticides with the GMO under Norwegian conditions, as well as changes to agronomy and possible 
long-term changes in the use of pesticides. 
 
 
The Norwegian Food Safety Authority  
 
In preparation for a legal implementation of EU-regulation 1829/2003, the Norwegian Environment 
Agency has requested the Norwegian Food Safety Authority (NFSA) to give final opinions on all 
genetically modified organisms (GMOs) and products containing or consisting of GMOs that are 
authorized in the European Union under Directive 2001/18/EC or Regulation 1829/2003/EC within the 
Authority’s sectoral responsibility. The request covers scope(s) relevant to the Gene Technology Act.  
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The Norwegian Food Safety Authority has therefore, by letter dated 13 February 2013 (ref. 
2012/150202), requested the Norwegian Scientific Committee for Food Safety (VKM) to carry out 
final scientific risk assessments of 39 GMOs and products containing or consisting of GMOs that are 
authorized in the European Union.  
 
The assignment from NFSA includes food and feed safety assessments of genetically modified 
organisms and their derivatives, including processed non-germinating products, intended for use as or 
in food or feed.  
 
In the case of submissions regarding genetically modified plants (GMPs) that are relevant for 
cultivation in Norway, VKM is also requested to evaluate the potential risks of GMPs to the 
Norwegian agriculture and/or environment. Depending on the intended use of the GMP(s), the 
environmental risk assessment should be related to import, transport, refinement, processing and 
cultivation. If the submission seeks to approve the GMP(s) for cultivation, VKM is requested to 
evaluate the potential environmental risks of implementing the plant(s) in Norwegian agriculture 
compared to existing varieties (e.g. consequences of new genetic traits, altered use of pesticides and 
tillage). The assignment covers both direct and secondary effects of altered cultivating practices.  
 
VKM is further requested to assess risks concerning coexistence of cultivars. The assessment should 
cover potential gene flow from the GMP(s) to conventional and organic crops as well as to compatible 
wild relatives in semi-natural or natural habitats. The potential for establishment of volunteer 
populations within the agricultural production systems should also be considered. VKM is also 
requested to evaluate relevant segregation measures to secure coexistence during agricultural 
operations up to harvesting. Post-harvest operations, transport, storage are not included in the 
assignment.  
 
Evaluations of suggested measures for post-market environmental monitoring provided by the 
applicant, case-specific monitoring and general surveillance, are not covered by the assignment from 
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Genetically modified maize Bt11 has been developed to provide protection against certain 
lepidopteran target pests, such as the European maize borer (Ostrinia nubilalis), and species belonging 
to the genus Sesamia (in particular the Mediterranean maize borer (Sesamia nonagrioides)). Protection 
from feeding damage by pest larvae is provided by expression in the tissues of Bt11 maize of a 
truncated form of a Cry1Ab protein encoded by a modified cry1Ab gene derived from the soil 
microorganism Bacillus thuringiensis subsp kurstaki HD-1. The mode of action of the Cry1Ab protein 
and other Cry proteins is to bind selectively to specific receptors on the epithelial surface of the 
midgut of larvae of susceptible insect species, leading to death of larvae through pore formation, cell 
burst and subsequently septicaemia. None of the target pests for maize Bt11 are present in the 
Norwegian agriculture. 
 
Bt11 was also genetically modified to express the enzyme phosphinothricin acetyl-transferase (PAT), 
encoded by the pat gene from the soil actinomycete Streptomyces viridochromogenes. Expression of 
PAT confers tolerance to the herbicide glufosinate-ammonium, the active ingredient in the herbicides 
Basta, Rely, Finale, and Liberty). Glufosinate-ammonium acts by inhibiting the plant enzyme 
glutamine synthetase, the only enzyme in plants that detoxifies ammonia by incorporating it into 
glutamine. Inhibition of this enzyme leads to an accumulation of ammonia in the plant tissues, which 
kills the plant within hours of application. PAT catalyses the acetylation of the herbicide 
phosphinothricin and thus detoxifies glufosinate-ammonium into an inactive compound. The PAT 
protein expressed in maize Bt11 has been used as selectable marker to facilitate the selection process 
of transformed plant cells, and is not intended for weed management purposes. 
 
The genetic modification in maize Bt11 is intended to improve agronomic performance only and is not  
intended to influence the nutritional properties, the processing characteristics and the overall use of 
maize as a crop. Event Bt11 has been crossed info both field maize and sweet maize varieties. 
 
Maize Bt11 (Unique Identifier SYN-BT Ø11-1) has been evaluated with reference to its intended uses 
in the European Economic Area (EEA), and according to the principles described in the Norwegian 
Food Act, the Norwegian Gene Technology Act and regulations relating to impact assessment 
pursuant to the Gene Technology Act, Directive 2001/18/EC on the deliberate release into the 
environment of genetically modified organisms, and Regulation (EC) No 1829/2003 on genetically 
modified food and feed.  
 
The Norwegian Scientific Committee for Food Safety has also decided to take account of the 
appropriate principles described in the EFSA guidelines for the risk assessment of GM plants and 
derived food and feed (EFSA 2011a), the environmental risk assessment of GM plants (EFSA 2010), 
the selection of comparators for the risk assessment of GM plants (EFSA 2011b), and for the post-
market environmental monitoring of GM plants (EFSA 2011c).  
 
The food/feed and environmental risk assessment of the genetically modified maize Bt11 is based on 
information provided by the applicant in the application EFSA/GMO/RX/Bt11 and notification 
C/F/96/05.10), and scientific opinions and comments from EFSA and other member states made 
available on the EFSA website GMO Extranet. The risk assessment is also based on a risk analysis 
report of Bt11 from the Australia New Zealand Food Authority (ANFZA 2000) and a review and 
assessment of relevant peer-reviewed scientific literature.  
 
It is emphasized that the VKM mandate does not include assessments of contribution to sustainable 
development, societal utility and ethical considerations, according to the Norwegian Gene Technology 
Act and Regulations relating to impact assessment pursuant to the Gene Technology Act. These 
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considerations are therefore not part of the risk assessment provided by the VKM Panel on Genetically 
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2  Molecular characterisation 
 
2.1 Information related to the genetic modification 
 
2.1.1 Description of the methods used for the genetic modification 
 
Bt11 maize was generated by transformation of a proprietary inbred maize line, H8540, with the 
vector pZ01502 to transfer two new genes, a truncated cry1ab gene (referred to as the cry1Ab gene) 
and the pat gene. The line was transformed using  protoplast transformation. The protoplasts were 
transformed with a larger DNA fragment obtained by a restriction digest of the plasmid pZO1502 with 
the enzyme Not I. According to the applicant, the Not I fragment was not expected to contain plasmid 
backbone DNA sequences. Regenerated plants were backcrossed to a selected line resulting in a plant 
called Bt11 maize.  
 
2.1.2 Nature and source of vector used 
 
The vector used for transformation was pZO1502. The pZO1507 vector is a derivative of pUC18. E. 
coli is the common host of the pUC18 plasmid. A vector map of pZO1502 is presented in Figure 1. 
The NotI restriction fragment containing the expression cassette was used for the transformation. The 
components are presented in Table 1 and 2 below. Their origin is also described. The NotI restriction 
fragment intended for insertion contained the cry1ab and the pat genes, but did not contain the 
ampicillin resistance gene.  
 
The elements intended for insertion are contained within the Not1 restriction fragment of plasmid 
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Table 2. Vector region intended for insertion from pZO1502 
 
 
Table 3. Source, size and intended function of constituents intended for insertion in Bt11 maize 
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Figure 1. Plasmid map of transformation vector pZO1502 
 
2.2 Information relating to the GM plant 
 
2.2.1 Description of the trait(s) and characteristics that have been introduced or 
modified 
 
Bt11 maize plants are protected from certain Lepidopteran insect pests (including Ostrinia nubilalis 
(European Maize Borer) and Sesamia spp.) and show tolerance to glufosinate-ammonium herbicides. 
Protection from feeding damage by pest larvae is provided by a truncated form of a Cry1Ab protein 
encoded by a modified cry1Ab gene derived from the soil microorganism Bacillus thuringiensis subsp 
kurstaki HD-1. The DNA sequence of the gene has been truncated at the 3’ end and modified to 
increase the level of expression in maize, but the amino acid sequence of the protein has not been 
altered (Perlak et al. 1991). The cry1Ab gene in Bt11 maize codes for the Cry1Ab protein, a truncated 
version of the δ-endotoxin produced by B.thuringiensis.  
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The tolerance to glufosinate ammonium herbicides is accomplished by expression of a pat gene, 
derived from the soil microorganism Streptomyces viridochromogenes strain Tu494, which encodes an 
enzyme: phosphinothricin acetyl transferase (PAT), capable of detoxifying the herbicide. 
 
According to the applicant, the truncated Cry1Ab protein and the PAT protein are produced within maize 
tissues and protect the plants from feeding damage by first and second brood ECB larvae. 
 
2.2.2 Information on the sequences actually inserted or deleted 
 
Bt11 maize was subjected to molecular analysis in order to determine the number of integration sites 
within the maize genome and the copy number (the number of copies of the DNA fragment used for 
transformation that were inserted in the GM plant), the integrity of the inserted cassettes and the 
absence of backbone sequences. Southern blot analyses were undertaken using a variety of DNA 
probes including the pat and cry1Ab genes, amp sequence and the entire plasmid to search for 
unintended insertions in the maize genome. 
 
Sequence analysis of the entire insert present in Bt11 maize indicate overall integrity of the insert and 
that the contiguousness of the functional elements has been maintained. PCR analysis and DNA 
sequencing were used to establish a detailed transgene locus structure and to verify the 5’ and 3’ 
junction sequences of the insert with the plant genome. These analyses indicate intactness of the 5’ 
and 3’ ends of the inserted cassettes. The sequence of the inserted fragment was obtained by 
sequencing PCR fragments amplified directly from the Bt11 maize genomic DNA. According to the 
applicant, the resulting sequence was identical to the sequence of the corresponding fragment in the 
plasmid. Therefore, the applicant concludes that no rearrangements occurred within the Not I fragment 
during gene transfer and integration into the plant genome. Sequence information indicates that no 
vector backbone fragments, including amp sequences, are inserted and fused to the inserted Not I 
fragment.  
 
2.2.2.1 The size and copy number of all detectable inserts, both complete and partial 
 
Data from Southern analysis indicate that single copies of the cry1Ab gene, pat gene and ColE1 origin 
of replication derived from the transformation plasmid pZO1502 are present in the Bt11 maize. 
According to the applicant, the Bt11 maize insert contains two copies of the 35S promoter, 
corresponding to the two copies of the promoter present in the transformation plasmid pZO1502. The 
applicant also concludes that the Bt11 maize insert does not contain any unintended backbone 
sequences from the transformation plasmid pZO1502.  
 
The structure of the Bt11 maize locus is represented in figure 2. As described previously the DNA 
inserted in the maize genome is the fragment obtained by NotI restriction of the plasmid pZO1502 
derived from pUC18 (figure 1). This fragment contains two gene cassettes: the 
CaMV35S/intron/Bt/nos cassette of the Bt gene and the CaMV35S/intron/pat/nos cassette of the pat 
gene. Additionally, it contains vector backbone upstream from the Bt cassette, between the two 
cassettes and downstream from the pat cassette.  
 
The size of the plasmid is 7,24 Kb, and the fragment integrated in the Bt11 maize is 6,2 Kb. 
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Figure 2.  Structure of Bt11 maize locus. 
 
 
2.2.2.2 The organisation of the inserted genetic material at the insertion site and methods 
used for characterisation 
 
According to the applicant, the entire Bt11 maize insert and flanking regions have been sequenced. 
The maize sequences flanking the Bt11 maize insert were also identified. A blast analysis of the 
sequences flanking the Bt11 maize insert was carried out against publicly available nucleotide 
databases (conf.). Bioinformatic analysis from 2008 confirmed the original analysis carried out by the 
applicant and supports the conclusion that the genomic sequences in both 5‟ and 3‟ regions flanking 
the insert of maize Bt11 show homology to highly repetitive, knob-associated sequences. 
 
DNA sequences at the junctions between the insert and the parent genome were determined. At the 5’ 
flank, approximately 350 bp of the plant DNA adjacent to the insert was sequenced. At the 3’ flank, 
approximately 540 bp of the plant DNA adjacent to the insert was sequenced. The 5’ and 3’ flanking 
sequences were screened for homologies with sequences found in public databases. According to the 
applicant, BLAST analysis of both the 5’ and 3’ regions of the Bt11 maize insert revealed homology 
primarily to the Zea mays 180 bp knob-associated tandem repeat. Knobs are components of the maize 
heterochromatin, a class of chromatin known not to be expressed. The 180 bp tandem repeated 
sequences have been characterized. Therefore, the applicant concludes that the insertion of the Not I 
fragment in the maize genome does not disrupt any endogenous maize open reading frame.  
 
 




2.2.2.4 Chromosomal location(s) of insert(s)  
 
According to the applicant, the inserted DNA is located on the short arm of chromosome 8. The insert 
is stably integrated into the plant chromosome and is inherited as a single dominant gene in a 
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2.3 Information on the expression of the insert  
 
2.3.1 Part of the plant where the insert is expressed 
 
To characterize the range of expression of Cry1Ab and PAT proteins in Bt11maize plants, the 
concentrations of Cry1Ab and PAT proteins were determined by ELISA in several plant tissues and 
whole plants at various growth stages (from whorl to senescence) from different hybrids of field and 
sweet maize.  
 
According to the applicant, the Cry1Ab protein was found in all tissues examined, with a decrease in 
concentration at the time of plant maturation and senescence. To update the information, the 
concentrations of Cry1Ab protein (the active insecticidal principle) were determined in several plant 
tissues and whole plants at four developmental stages (whorl, anthesis, seed maturity and senescence) 
in two field maize hybrids. The quantity of Cry1Ab protein was also estimated on a per-acre and a per-
hectare basis. Levels in pollen were below the lower limit of quantification, < 0.08 µg/g fresh wt. 
pollen and < 0.15 µg/g dry wt. pollen. Across all plant stages, mean Cry1Ab levels measured in leaves, 
roots and whole plants ranged from ca. 10 - 22 µg/g fresh wt. (12 – 154 µg/g dry wt.), 2 – 4 µg/g fresh 
wt. (9 – 22 µg/g dry wt.), and 4 – 9 µg/g fresh wt. (6 – 70 µg/g dry wt.), respectively. Mean Cry1Ab 
levels measured in grain at seed maturity and senescence were 1 – 2 µg/g fresh wt (2 µg/g dry wt.). 
The level of Cry1Ab was generally similar between hybrids for each tissue type at each time point. 
 
The application also cover marketing and trading on the European market of Bt11 sweet maize for 
immediate consumption, for the consumption of tinned and frozen sweet maize and for the further 
processing into sweet maize powder. 
 
The applicant has also performed a specific analysis to determine the level of the Cry1Ab protein in 
tissues from three Bt-11 sweet maize hybrid varieties and control lines with a similar genetic 
background from field tests in 1996. The Cry1Ab protein levels in grains tested at prime harvest stage 
was also assessed in these sweet maize hybrids that had been canned. The level of the Cry1Ab protein 
in Bt11 sweet maize hybrids grain at prime harvest was 1.97 ± 0.36 µg/g fresh weight, and at 21 days 
post prime harvest 2.98 ± 1.12 µg/g fresh weight. The range of Cry1Ab in grain for all three sweet 
maize hybrids was 0.51 to 3.80 µg Cry1Ab/g fresh weight. Cry1Ab protein was not detectable in any 
of the canned maize samples tested. The applicant concludes that since the Cry1Ab protein was not 
detected in canned maize and the levels of Cry1Ab in grain for all Bt11 maize varieties (field and 
sweet maize) were low, dietary exposure to the novel protein is expected to be very low. 
 
According to the applicant, the level of the PAT protein was determined using Bt11 field maize plants; 
measurable levels (ng/g) were only found in leaves, silk and tassel. For grain, pollen, root and stalk 
concentrations were below the limits of detection. The PAT protein is present at less than 0.000008% 
fresh weight and 0.00016% of the total maize grain protein. 
 





2.4 Genetic stability of the insert and phenotypic stability of the GM 
plant  
 
2.4.1 Genetic stability of the insert 
 
The genetic stability of the inserted DNA in Bt11 maize was shown by both a classical approach and a 
molecular approach using Southern blot analysis on genomic DNA.  
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The Bt11 maize was subjected to a backcrossing program with the elite line H8540. The lines BC3 and 
BC6, developed as part of this program, were used to evaluate genetic stability. BC3 was developed 
from 3 backcrosses with H8540 and BC6 from 6 backcrosses. According to the applicant, no 
differences in banding pattern were observed between the DNA from these generations demonstrating 
the stability of the inserted DNA.  
 
Segregation data for glufosinate ammonium tolerance and European maize borer resistance were 
collected at different points in the backcrossing experiment. BC3 and BC6 plants, identified as 
containing the cry1Ab and pat genes, were subjected to selfing experiments. According to the 
applicant, the results indicate heritability and stability of the two genes in the Bt11 maize. Data 
support the presence of a single insertion that segregates according to Mendelian inheritance patterns.  
 
Restriction fragment length polymorphism (RFLP) mapping was used to determine the location of the 
novel genes in Bt11. The progeny of Bt11 plants crossed with the two inbred maize lines were 
screened with RFLP probes, corresponding to different regions of the corn genome. Comparison of the 
genotypes of the progeny with isogenic controls demonstrated that the site of integration for the 
genetic material in Bt11 maize is located on the long arm of chromosome 8. 
 
 
2.4.2 Phenotypic stability of the GM plant 
 
According to the applicant, no differences in the agronomic and phenotypic characteristics were found 
between the Bt11 maize and the non-transgenic counterpart during field trials at different locations 
(Spain, France, Italy and Portugal) conducted between 1994 and 2006 that would indicate unexpected 
pleiotropic effects of the genetic modification (Final reports at JRC web page). 
 
The stability of the inserted DNA in Bt11 maize was demonstrated by a Mendelian inheritance pattern. 
The segregation of the cry1Ab and pat genes and their phenotypic traits was followed over multiple 
generations. F1 plants (first generation hybrids) were identified as containing the cry1Ab and pat 
genes. These plants were self-fertilised to produce the S1 population. This S1population was screened 
for protection against the European corn borer and for tolerance to glufosinate- ammonium. The S1 
plants were again self-fertilised. The insect protection and herbicide tolerance traits were then 
backcrossed into two genetic backgrounds (H8540 and 977), and in some cases, followed by further 
self-fertilisation. 
 
Seed was collected from maize plants exhibiting both new traits representing different backcross 
stages and planted in the field for analysis in 1994 and 1995. Plants were tested for protection against 
the European corn borer and tolerance to glufosinate ammonium. All plants were either both tolerant 
to the herbicide and protected against insect attack or susceptible to both with segregation patterns 




The molecular characterisation data indicate that a single copy of the transgenic insert with the cry1Ab 
and pat genes is integrated  in the nuclear genome of maize Bt11, and that it is inherited as a dominant, 
single locus trait. Appropriate analyses of the integration site, inserted DNA sequence, flanking 
regions, and bioinformatics have been performed. The VKM GMO Panel considers the molecular 
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3 Comparative assessment 
 
3.1 Production of material for the comparative assessment 
 
The application EFSA/GMO/RX/Bt11 for food and feed use, import and processing of maize Bt11 
within the EU presented compositional data on seed and forage material collected in field trials 
performed in the USA in 1995, 1996 and 1998, and in France in 1998. These studies have been 
conducted on Bt11 seeds and major components in inbred and hybrid lines at different stages of 
maturity are assessed and the results are compared with their respective near-isogenic controls. In 
addition, the applicant has provided data from compositional analysis of Bt11 maize plants grown in 
greenhouses in Europe in 1999.  
 
The applicant has provided data on the original transformant (H8540 and hybrids) and different maize 
hybrids widely used in food and feed production. This includes several field/field maize and sweet 
maize lines that have been developed from conventional breeding of the original transformed line.  
(See Table 1, Appendix 1 for a complete summary of the lines analysed).  
 
Studies submitted by Syngenta Seeds Inc. 
 
• Compositional analysis of Bt11 maize: determination of the substantial equivalence — chemical 
composition analysis done with Bt-11 maize with a European background.  
(Greenhouse study in Europe in 1999) 
 
• Compositional analysis of Bt11 maize: determination of the substantial equivalence — chemical 
composition analysis done with Bt-11 maize with a US background. Part 1: Properties of grain 
produced from ECB protected maize hybrids; Part 2: Characterization of grain attributes of normal, 
wild-type maize hybrids and the Bt11 converted iso-hybrid counterparts; Part 3: Analyses of fatty acid 
and amino acid profiles of grain from Bt-11 maize. Report No. NSB-004-97. 
(Field trials conducted in the USA in 1995 (6 sites) with six field maize lines developed from 
conventional breeding with the original transformant) 
 
• Comparison of vitamin and mineral composition of Bt11 maize and non-modified maize hybrids. 
Report No. NSB- 004-97. Novartis Seeds. 
(Field trials conducted in the USA in 1995 (3 sites) with six field maize lines developed from 
conventional breeding with the original transformant) 
 
• Comparison of nutritional composition of fresh and canned grain prepared from Attribute insect 
protected and control sweet maize hybrids. Report No. NSV-002-98. Novartis Seeds Inc. 
(Field trials conducted in the USA in 1996 (1 site) with six sweet maize lines developed from 
conventional breeding with the original transformant) 
 
• Goy PA (1999) Novartis Seed’s genetically modified Bt11 maize: biochemical composition of grain 
from plants treated with a glufosinate ammonium herbicide. 
(Field trials conducted in France in 1998 (2 sites) with three field maize hybrids) 
 
• Goy PA (2000) Novartis Seed’s genetically modified Bt11 sweet maize: further determination of the 
biochemical composition of kernel- analysis of secondary metabolites. 
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3.2 Compositional Analysis 
 
3.2.1 Study 1: Analysis of Bt11 maize grown in greenhouse in Europe (1999) 
 
The components of several lines and hybrids of the Bt11 maize, derived through backcrossing from 
the original transformant, were analyzed and compared to isogenic non-modified lines and hybrids. 
The following greenhouse grown plants were analysed: an inbred line (H8540-Bt), a hybrid line 
(hybrid Bt+/Bt-) and their respective controls (isogenic non-modified H8540 and control hybrid). 
Between 45 and 56 ears were taken from each plant. Ears were harvested and dried four months after 
sowing and 500 g samples were analysed.  
 
The following parameters were analysed: moisture, total nitrogen, ash, starch, cellulose, xanthophyll, 
fatty acid and amino acid composition.  Statistical comparison with STATITCF software was made on 
the values of two replicate analyses, except in the case of xanthophyll, fatty acids and amino acids, 
where data points are the result of a single analysis. 
 
Proximates 
All values for proximates were within the range, except total nitrogen content (Table 1). The total 
nitrogen content of both Bt11 maize and non-transgenic maize were higher than the spectrum ranges 
found in the literature. As the protein content is influenced by the available soil nitrogen, the increase 
could be caused by the fertilizer used in culturing of the plants in the greenhouse.  
 
 






A single analysis was done on 500g samples of grains from Bt+/Bt+ H8540 (number of ears 
n=54), isogenic control H8540 (number of ears n=56), Bt+/Bt- hybrid (number of ears n=50), 
control hybrid (number of ears n= 45). No range is available for arachidic acid, gadoleic acid or 
behenic acid. All other values regarding the fatty acids were within the range (Table 2). There were no 
differences in these values greater than 10% (which allows for experimental error) between the 
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A single analysis was done on 500g samples of grain from Bt+/Bt+ H8540 (number of ears n=54), 
isogenic control H8540 (number of ears n=56), Bt+/Bt- hybrid (number of ears n=50), control hybrid 
(number of ears n= 45). The experimental data regarding the amino acid composition are generally 
higher than the bibliographical ones (Table 3). According to the applicant, the reason is the high 
nitrogen content of the analysed material. The bibliographical values originated from maize grains 
have total nitrogen content of approximately 9.5%. According to the applicant these data, therefore, 
need to be corrected to give comparable values. Protein levels were higher than the normal range for 
all plants assessed. The data were multiplied by 1.33, the corrective factor shown in the total nitrogen 
analysis (Table 1). As protein content is affected by soil nitrogen, it is possible that the fertiliser used 
caused the high level of nitrogen for all plants in the study. 
 
After correction and taking in account experimental error (10%) the values are included in the range 
(Table 3). Comparison between Bt11 maize and control maize indicate no difference except for 
glutamic acid, which is in the limit of the allowed variation for the hybrid (experimental error of 10%). 
 
The levels of glutamine, asparagine and tryptophan were not determined. Tryptophan is one of the 
essential amino acids and one of the limiting amino acids in maize. No spectrum or literature ranges 
were available for some of the amino acids, because some of these analyses are not routinely carried 
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3.2.2 Study 2: Analysis of Bt11 field maize grown in USA (1995) 
 
Grain property studies were conducted on Bt11 maize hybrids and non-transgenic maize hybrids 
grown in 3-6 field locations in the USA in 1995. The following traits were considered: grain size, 
density and the content of proximates: starch , protein , oil  and  fiber expressed as percentage of dry 
weight, and fatty acid,amino acid, and mineral and vitamin profiles.  
 
Dataset 1: 
An analysis of the major components and nutritional qualities of two elite Bt11 field maize lines 
(X6534CBR, X7634CBR) developed from conventional breeding with the original transformant, has 
been assessed. In this trial, the Bt11 hybrids and their near-isogenic controls (X6534 and X7634) were 
grown in three field locations in the USA (Table 1, Appendix 1).  
 
Grains from the Bt11 hybrids and the conventional counterparts were analysed for percentage of 
starch, protein, oil and fibre. No significant differences were detected between the Bt hybrids and the 
control hybrids (p>0.05) (Table 4).  The grains from insect-resistant maize hybrids were comparable to 
control hybrids regarding the content of starch, protein, oil and fibre and fell within the normal ranges 
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A second nutritional study on Bt11 field maize that included additional hybrids was conducted. Three 
to five ears were picked from the center two rows of a four row strip plot for each hybrid per two sites 
within three geographical regions to give a total of six locations per hybrid. Two of the hybrids had a 
‘northern’ (early-season) genetic background and two had a ‘southern’ (mid-late-season) genetic 
background. The hybrids were derived from separate backcross conversion processes using the same 
original transformation event.  
 
Proximates 
The compositional data for the Bt11 maize and control maize plants were analysed for significant 
differences by Analysis of Variance. The components measured were % protein, oil, starch and fibre 
(Table 5). Grain from the early season (northern hybrids) Bt11 maize hybrids (X4334CBR and 
X4734CBR) have a significantly lower protein content than grain from the control maize lines (p<0.05 
and p<0.01), respectively). All other components were comparable between the Bt11 maize hybrids 
and their respective control maize lines. 
 
Although the protein was lower in the northern hybrids, there is a lack of consistent differences 
between the non-modified hybrids and their genetically modified equivalents. These results may 
indicate that the effects observed, are not likely to be a result of the genetic modification itself but 
more likely from differences arising out of an incomplete backcross conversion in the normal breeding 
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Fatty acids and amino acids 
Fatty acid and amino acid analyses were performed on twenty grain samples obtained from Bt11 and 
non-transgenic control maize. Two separate analyses were performed. In the first analysis, variation 
between Bt11 maize and non-transgenic control maize were analysed to determine whether there were 
significant differences between Bt11 maize and the control maize.  In the second analysis, only the 




Amino acid analysis was performed on twenty grain samples from Bt11 maize (6534CBR and 
4734CBR) and non-transgenic control maize (N6800, N4640, N4242, N5220, N5666, N6223, N6822, 
N7070 and N7590). Significant difference between Bt11 maize and non-transgenic control maize were 
found for cysteine and arginine (p <0.05). For cysteine Bt11 maize (4734CBR) was lowest in content 
at 0.170. The range among the maize plants was from 0.170 to 0.230. This difference is not consistent 
for all genetically modified maize hybrids and is consistent with the variability that is observed 
between lines. Some variability may arise as a result of incomplete backcrossing. This variation is not 
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Fatty acid  
Fatty acid analyses were also performed on the grain sampled as described above. The grain was 
sampled from two locations, three samples per line from two Bt11 hybrid maize lines X6534CBR and 
X4734CBR and their genetically equivalent controls (N6800 and N4640 respectively). Additionally, 
grain from another seven non-modified reference hybrids was analysed (N4242, N5220, N5666, 
N6223, N6822, N7070 and N7590). As outlined above for the amino acid analysis, two separate 
statistical analyses were performed. The first analysed the variation between hybrids to determine 
whether there were significant differences between them. The second study analysed differences 
specifically between genetically modified hybrids and their isogenic controls. The results are shown in 
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Table 7. A statistical analysis to determine the variation between hybrids, as described above for the 
amino acid analysis, found no significant differences between the hybrids for fatty acid values 
(p>0.05). 
 
A second statistical analysis of the fatty acid values investigated specifically differences between the 
genetically modified maize hybrid plants versus the non-modified control hybrids. Significant 
different between Bt11 maize and non-transgenic control maize were found for palmitic- and stearic 
acid. According to the applicant, Bt11 maize falls within the range of non-transgenic control maize for 
palmitic- and stearic acid content (Table 7).  
 
 




An analysis of the major components and nutritional qualities of elite Bt11 field maize lines has also 
been assessed. These lines are derived from the original transformant. Two genetically modified Bt11 
hybrid maize lines and their near-isogenic controls were grown in three field locations in the USA in 
1995. 
 
Vitamins and minerals 
One-pound (2.24 kg) samples of grain were taken from each of three locations from the two Bt 11 
maize hybrids N4242-Bt and N4640-Bt and their corresponding near-isogenic non-modified hybrids 
and analysed for their vitamin and mineral content.The data were analysed to determine if there were 
significant difference between the Bt11 maize and the non-transgenic control maize. For each analysed 
parameter, means and standard deviation were calculated. Transgenic maize was compared to non-
transgenic control by t-test (p = 0.05).  
 
The grain was analysed for the minerals copper, magnesium, manganese and zinc as well as the 
vitamins folic acid, niacin, vitamin B1 and vitamin B2 (Table 8). No significant differences (p=0.05) 
between Bt-11 maize hybrids and their corresponding control hybrids were observed for any of the 
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3.2.3 Study 3: Comparison of nutritional composition of fresh and canned Bt-11 sweet 
maize (North America 1996) 
 
A fifth analysis of Bt-11 maize lines was done, specifically to assess the nutritional value of three Bt-
11 sweet maize varieties.  
 
Maize was harvested from the Bt-11 sweet maize hybrids, Bt 98- 0943, Bt 95-0937 and Bt 95-0941, 
and from their corresponding near-isogenic non-modified hybrids, grown in 1996 at one location in 
the North America. The field trials were designed following a random block design with three 
replicate plots of each genotype. Data for each genotype were subjected to analysis of variance. For 
each analyte the statistical significance of the genotype effect was determined using a standard F-test 
at the 5% probability. The significance of the location x genotype interaction was also assessed using 
an F-test. The results were compared to compositional analysis data for grain and forage published in 
the literature and in compositional analysis databases.  
 
Ten ears of each of the hybrids were harvested at prime harvest and analysed as fresh maize on the 
cob. Maize from each hybrid was canned and also analysed (processed maize analysis). Fresh and 
canned sweet maize was analysed for moisture, protein, fat, ash, carbohydrates, fibre, vitamins and 
minerals (Table 9). Given that there was only duplicate analysis of one sample taken for each line, no 
statistical analysis was performed. Comparable nutritional composition was observed between Bt11 
sweet maize (Bt 95-0943, Bt 95-0937 and Bt 95-0941) and corresponding non-transgenic hybrids 
(Jubilee, Bonus and Empire) for the selected compounds (Table 9). According to the applicant, the 
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3.2.4 Study 4: Analysis of Bt11 field maize and sweet maize grown in North America 
(1998) 
 
Compositional analyses of three Bt11 maize hybrids and non-transgenic control maize, grown in one 
location, were analysed. An F test was conducted to see whether the values obtained for the Bt11 
sweet maize were statistically significantly different from the values obtained for the isogenic hybrids, 
taking the various hybrids as “repetitions” (P = 5%). The values obtained were compared to those 
listed for maize grain in the NOTIS plus database, when available (Table 11). The following traits 
were considered: furfural, p-coumaric acid, ferulic acid, myo-inositol and raffinose.  
 
Secondary metabolites 
There are no generally recognised anti-nutrients in maize at levels considered to be harmful, but for 
the purposes of assessment of substantial equivalence, the OECD has asked for analytical data for the 
following secondary metabolites in maize: ferulic acid, p-coumaric acid, furfural, inositol, phytic acid, 
raffinose and trypsin inhibitor.The study indicate that grains from Bt11 sweet maize are substantially 
equivalent to grain from non-transgenic maize, by showing that the levels of furfural, p-coumaric acid, 
ferulic acid, myo-inositol and raffinose are similar in both types of maize (Table 10). The values were 
not significantly different at P = 5%, for any of the parameters measured. One striking difference 
observed are the higher amount of myo-inositol in one hybrid pair (GS0975 2330 and the 
corresponding isogenic GSS9377 322), compared to the other hybrids. Phytic acid and trypsin 
inhibitor were not analysed. 
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Table 10. Secondary metabolites composition for Bt11 sweet maize and control maize  
 
 
The values obtained in Table 10 were compared to those listed for maize grain in the NOTIS plus 
database, when available. The comparison is shown in Table 11. Significant differences were 
observed. According to the applicant, these differences are most likely due to the fact that the values 
reported in the NOTIS plus database are for “field maize”, whereas the analyses reported here were 
conducted on sweet maize. Sweet maize has a different biochemical composition than field maize, the 
major difference being that energy is stored in the endosperm of the sweet maize grain in the form of 
various “sugars”, whereas field maize accumulates starch. According to the applicant, differences are 
not unexpected. No literature values for these compounds of sweet maize were found.. 
 




3.2.5 Study 5: Analysis of Bt11 field maize lines treated with herbicide in Europe 
(1998) 
 
An additional study was done to assess the potential effects of herbicide treatment on the major 
components of the maize grain. Three Bt-11 hybrids representing different maturity types (Madera, 
Manuel and Magister) and their isogenic controls were grown in open fields at two locations in France 
in 1998.  
 
An F test was conducted to see whether the values obtained for the “treated Bt11 hybrids”, the 
“untreated Bt11 hybrids” and the “non-modified control hybrids” were statistically significantly 
different at p<0.05, taking the various hybrids as “repetitions”. The evaluation of the data was done by 
comparing the values obtained for the “treated Bt11 hybrids” to those obtained for the “untreated Bt11 
hybrids” and for the “control hybrids”. 
 
Proximate analysis (carbohydrate, protein, fat and fibre), fatty acids and amino acid composition were 
compared between transgenic crops treated with a glufosinate ammonium herbicide (Liberty®) at a 
rate of 2.25 L/ha active ingredient at the 3 and 6–7 leaf stages and untreated transgenic and isogenic 
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controls (Table 12). Values presented in this experiment are not directly comparable to values for 




No significant differences in the content of proximates were observed between the different groups of 
hybrids, for none of the parameters measured (Table 12). 
 
Table 12. Proximate composition for Bt11 and1 maize and control (treated or untreated with glufosinat 




Bt11 hybrids, untreated or treated with glufosinate ammonium, as well as control hybrids gave 
comparable results, with the exception of proline and alanine (Table 13).  When comparing the three 
“treatments” using an F test, the values obtained for glutamic acid, proline, alanine, isoleucine, leucine 
and phenylalanine were statistically different at P = 5%. However, when comparing only the “treated 
Bt11 hybrids” to the “control hybrids”, the values for glutamic acid, isoleucine, leucine and 
phenylalanine were not statistically significantly different. According to the applicant, concerning 
proline and alanine, the differences observed are unlikely to be due to the genetic modification itself in 
interaction with the glufosinate ammonium treatment, as not all three hybrids showed this. The 
difference between the treated modified and non-modified line was not consistent for all lines and may 
be a result of variability between the lines. This difference is not considered to raise safety or 
nutritional concerns.  
 
The values for proline and alanine for each of the three hybrids is shown in detail in Table 14. The 
difference between the treated modified and non-modified line was not consistent for all lines and may 
be a result of variability between the lines. This difference is not considered to raise safety or 
nutritional concerns. The levels of glutamine and tryptophan were not determined. Tryptophan is one 
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Table 13.  Amino acid composition for Bt11 and control maize (treated or untreated with glufosinate-
ammonium) (ANZFA 2000). 
 
 





The results of the determination of palmitic acid, stearic acid, oleic acid, linoleic acid and linolenic 
acid are presented in Table 15. The values obtained for the “treated Bt11 hybrids”, the “untreated Bt11 
maize” and the “non-modified control maize” was comparable. An F test confirmed the lack of 
significant differences at P = 5%. 
 
Table 15. Fatty acid composition for Bt11 and control maize (treated or untreated with glufosinate- 
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3.2.6. Determination of DIMBOA levels in Bt11 maize (field maize and sweet maize) 
 
DIMBOA (2,4-dihydroxy-7-methoxy-1,4-benzoxazin-3-one) is a naturally occurring hydroxamic acid, 
a benzoxazinoid. DIMBOA is a powerful antibiotic. In maize, DIMBOA functions as natural defense 
against European corn borer larvae and other damaging pests. MBOA (on 6-methoxybenzoxazolin-3-
one (MBOA) is a degradation products of DIMBOA and was analysed in Bt11 maize. Bt11 maize has 
been back-crossed into several field maize and sweet maize varieties through traditional breeding 
methods. Therefore, “Bt11 field maize” and “Bt11 sweet maize” represents the same transformation 
event. The report presents data on the level of MBOA in seedlings of 4 different Bt11 maize hybrids 
(N6800Bt, N4640Bt, N4242Bt and Attribute), compared to their (near) isogenic hybrids (N6800, 
N4640, N4242, Attribute non-modified control). One of the hybrid pair tested was a sweet maize 
variety. No statistically significant differences were found.  
 
Considerable plant-to-plant variability was observed, as reflected by the large standard deviation. A t-
test was conducted and indicates that the DIMBOA levels (as determined after conversion to MBOA) 
were not significantly different between the Bt11 maize plants and the isogenic controls, for any of the 
hybrid pairs analyzed. An F-test was also conducted, taking all data together and considering the 
“Bt11-trait” as a “treatment”. No statistically significant difference was identified this way either. 
 
No significant differences in the levels of DIMBOA were observed between the genetically modified 




3.3 Agronomic and phenotypic characters  
 
According to the applicant, agronomic and phenotypic data on maize Bt11 and its non-transgenic 
counterpart were collected from field trials conducted in Spain, France, Italy and Portugal between 
1994 and 2006, and in the USA and Canada in 1994. The technical dossier (Appendix 4), however, 
contains only a draft summary of the results obtained in the USA and a visual comparison of Bt11 to 
its non-modified isogenic hybrid in France. Data on the mentioned field trials in Spain, France, Italy 
and Portugal are not presented in the application EFSA-GMO-RX-Bt11.  
 
 
North America 1994 
Four generations of backcrossing (to BC4) supplemented by selection, were used to transfer the 
chromosome fragment containing Btk coding sequence into the genetic background of elite maize 
inbred lines. A series of three indepenfield conversions of the inbred 2043 were derived through 
parallel backcrossing schemes. Likewise, two indepenfield conversions of the inbred 2044, were used 
to obtain a Btk version of the original 2044.These BC4 derivates were then subjected to extensive 
experimental analysis to assure that they represented adequate recoveries of the essential features of 
the original elite lines.  
 
The two 2044 conversions, along with the original 2044, were crossed to a series of five, unrelated, 
elite inbred lines to produce F1 hybrid seed for evaluation in replicated trials in 1994. Eighteen hybrids 
were produced for evaluation. Evaluation consisted of planting each hybrid at each of 17 locations 
which were distributed across eight US States and one Canadian providence. The trial design at each 
site was a randomized complete block design with two replicates. Each plot was represented by two 
rows (paired) of 20 feet in length, including three foot alleys. The plant population varied within the 
range of 25.000 to 27.000 plants per acre at each location. Notes and measures were taken on the plots 
during the growing season, as is usual for commercial variety trials. At harvest, a grain combine, 
which is adapted to harvest of maize plot trials, was used to determine plot yield and grain moisture at 
harvest.  
 
Data were collected for the following agronomic and phenotypic characteristics: yield, grain moisture, 
stalk lodging rating, root lodging rating, ear height, plant height, heat units to silking, heat units to 
pollen shed and intactness rating (data not shown). The parameter “intactness rating” was however not 
specified, and the method for its evaluation not indicated.Data was subjected to factorial analysis of 
variance using the SAS GLM Procedure. Contrast was used to test the significance of the difference 
between the original, non-transformed, 2044 line effects and those of the transformed derivates. An 
ifieldical process was used in testing the Btk conversions of the elite inbred 2043. Btk-converted lines 
were tested in combination with 6 elite inbreds and resulting hybrids were evaluated in 17 locations. 
 
The VKM GMO Panel considered the data presented for the USA/Canada trial inadequate for a 
complete evaluation, as information on the varieties assessed and their relationship (Bt hybrids and 
conventional control), use of the herbicides, pesticides and the applied fertilizer regime is missing. 
Furthermore information is missing on environmental conditions during trials. A complete breeding 
history of the maize varieties analysed in the trials should be provided as well as a complete 
description of the agricultural management applied in each location. In particular, as this GMO is 
tolerant to glufosinate-ammonium, a herbicide-treated and a herbicide untreated variant must be 
included and potential differences assessed, which are due to the different treatments. 
 
Apart from the incomplete presentation of material and methods used in the USA/Canadian field trials 
in 1994, only a summary of results is contained in the submitted study. No raw data are presented or 
data on a per location basis. 
 
According to the applicant, statistically significant differences were observed between the elite line 
2044 and the Bt11 conversions for the parameters stalk lodging (p<0.001), heat units to silking and 
pollen shed (p<0.05) and intactness rating (p<0.01) (data not shown). Similarly for 2043 and its 
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derivates, differences were observed for moisture (p<0.05), stalk lodging (p<0.001) and intactness 
rating (p<0.001). The parameters stalk lodging rate and intactness rating (general performance) are 
expected to be affected by maize borer damage, and thus the results are as expected. According to the 
applicant, the significant differences between the test line and control for heat units to silking and 
pollen shed and moisture at harvest are related to different genetic backgrounds and different 
maturities of the elite lines. 
 
France 1995 
During the field trial in one growing season in France, visual observations were taken on maize Bt11 
(H8540 Bt11) and the non-transgenic counterpart (near-isogenic line H8540). The following 
agronomic and phenotypic parameters were assessed: anthocyanin coloration at the level of the ear, 
tassel, leaf, internodes and glumes; plant and tassel length, grain type, resistance to pests and diseases, 
number of primary lateral branches, height of insertion of ears, length of peduncle, shape/length of 
ears and number of rows of grain.  
 
According to the applicant, the data from the field in France confirmed the equivalence of Bt11 maize 
phenotype to its non-transgenic counterpart. Furthermore, no differences in the agronomic and 
phenotypic characteristics were found between the Bt11 maize and the non-transgenic counterpart 
during field trials at different locations in Spain, France, Italy and Portugal conducted between 1994 
and 2006 that would indicate unexpected pleiotropic effects of the genetic modification.  
 
The data presented for the 1995 France trial are however insufficient for an assessment of agronomic 
behavior of maize Bt11. Appendix 4 contains only a overview over the parameters assessed and , 
visual comparison of Bt11 to its near-isogenic hybrid. No data from the analyses of phenotypic 
characters from these field trials is provided in the application. Further, no information is contained on 
the location of the sites, the methods applied to assess the indicated parameters, the agronomic 
management conditions (herbicide, pesticide, fertilizer regime), the environmental conditions, the field 
trial design (replication, plot size etc) and the breeding history of the GM and non-GM varieties used.  
 
Data on the mentioned field trials in Spain, France, Italy and Portugal are not presented in the dossier. 
Appendix 4 contains only a draft summary on results obtained in the USA and a visual comparison of 
Bt11 to its non-modified isogenic hybrid in France. 
 
Due to the insufficient data provided by the notifier, no conclusions can be made on the agronomic 
behavior and characteristics of the GM maize Bt11 as well as the related phenotypic characteristics 




Comparative analyses of data from field trials located at representative sites and environments in 
North America and Europe indicate that maize Bt11 is compositionally equivalent to its conventional 
counterpart, with the exception of the herbicide tolerance and insect resistance traits, conferred by the 
expression of the Cry1Ab and PAT proteins. However, data on the amino acid tryptophan, is only 
given in one out of six studies. Based on current knowledge, the VKM GMO panel concludes that 
maize Bt11 is compositionally equivalent to conventional maize. 
 
The data provided by the applicant are not sufficient to show that Bt11 maize is phenotypically and 
agronomically equivalent to conventional near-isogenic maize lines. The agronomic assessment data 
are provided from one growing season in the North America and one growing season in France. This 
is not considered to be sufficient for representative testing of agricultural environments. 
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4 Food /feed risk assessment 
 
According to ISAAA (The International Service for the Acquisition of Agri-biotech Applications) the 
trade name of Bt11 is Agrisure™ CB/LL, or Attribute (Bt Maize registrations-2010). 
 
4.1 Product description and intended uses 
 
The genetic modification in Bt11 field maize will not impact the existing production processes used 
for maize. All Bt11 maize products will be produced and processed for use in food, animal feed and 
industrial products in the same way as other commercial maize. The Bt11 field maize and all food, 
feed and processed products derived from Bt11 field maize are expected to replace a portion of similar 
products from commercial maize, with total consumption of maize products remaining unchanged. 
The total anticipated intake/extent of use of maize and all food, feed and processed products derived 
from maize will remain the same. 
 
The Bt11 sweet maize is grown exclusive (100 %) for human consumption. By-products from 
processing are used as animal feeds. Sweet maize to be used as fresh vegetable is harvested at an 
immature stage, around 24 % dry matter. According to Syngenta about 12 million hectares Bt11 sweet 
maize were planted in USA in 2012 (information on Syngenta web-page). 
 
4.2 Processing of maize 
 
Food manufacturing of Bt11 field maize includes many harsh processing steps, e.g. cooking, heating, 
high pressures, pH treatments, physical shearing, extrusion at high temperatures etc. under which the 
majority of proteins are denatured, which also applies to CRY1Ab1 and PAT proteins (Hammond et 
al. 2011). 
 
Bt11 sweet maize is able to consumers as fresh vegetable (maize on the cob) to be eaten as steamed 
cooked, or roasted on a barbecue. Sweet maize is also processed for freezing, canning and dehydrated 
powder. The canning process includes a cooking/sterilisation process at or above 110 ○C, and duration 
of approximately 10 minutes. The freezing process includes a short bleaching process. Generally, the 
grain are exposed to steam (100 ○C) from a few second to one minute.  
 
4.3 Toxicological assessment 
 
The potential toxicity of Bt11 maize expressing the Cry1Ab and PAT protein has been assessed in 
toxicity study in rofields, broiler chicken, pigs and cattle.  
 
4.3.1 Toxicological assessment of the newly expressed protein 
 
The cry1Ab gene was originally obtained from Bacillus thuringiensis strain. There is no evidence of 
Cry1Ab having harmful effects on the health of humans or animals (EPA 1995a; McClintock et al. 
1995; EPA 1996). The Cry1Ab protein has a very specific mode of action and selective toxicity 
against certain lepidopteran and coleopteran insect pests (target organisms).  
 
Test for possible binding of Cry1Ab to proteins of bovine intestinal cells 
Shimada et al. (2006b) performed immunohistochemical and ligand blot analysis to investigate the 
interaction of Cry1Ab toxin with bovine intestinal epithelium. Shimada et al. (2006) found that 
Cry1Ab binds to actin, but not to aminopeptidase N, cadherin, or alkaline phosphatase, all which are 
cell membrane receptors or candidate proteins for development of toxicity in susceptible insects cells. 
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The results indicate that Cry1Ab toxin is able to bind to cytoskeletal actin, but that the bovine 
intestinal epithelial cells lack membrane receptors, which are necessary for the toxin to exert its 
toxicity on cells. 
 
Test for possible binding Cry1Ab to mammalian cellular brush border membrane vesicle (BBMV) 
Shimada et al. (2006a) investigated the affinity of Cry1Ab toxin, a lepidopteran-specific Cry1-type 
toxin, to the cellular BBMV of two mammalian intestinal cells as well as the effect of the toxin on the 
membrane potential of three mammalian intestinal cells compared to its effects on the silkworm 
midgut cell. Shimada et al. (2006) found that Cry1Ab toxin did bind to the bovine and porcine BBMV, 
but far more weakly than it did to the silkworm midgut BBMV. Although the silkworm midgut cells 
developed severe membrane potential changes within 1 h following the toxin treatment at a final 
concentration of 2 µg/ml, no such membraneous changes were observed on the bovine, porcine, and 
human intestinal cells. The present in vitro results suggest that, although Cry1Ab toxin may bind 
weakly or nonspecifically to certain BBMV components in the mammalian intestinal cell, it does not 
damage the cell's membrane integrity, thus exerting no subsequent adverse effects on the cell. 
 
Test for possible toxic potential of Cry1Ab on porcine culture intestinal cells 
Bondzio et al. (2013) performed in vitro testing on porcine culture intestinal cells (IPEC-J2) with 
Cry1Ab protein. For comprehensive risk assessment they used WST-1 conversion and ATP content as 
metabolic markers for proliferation, lactate dehydrogenase release as indicator for cells with 
compromised membrane and transepithelial electrical resistance as parameter indicating membrane 
barrier function. The results were compared to the effects of valinomycin, a potassium ionophore, 
known to induce cytotoxic effects in most mammalian cell types. Whereas no toxicity was observed 
after Cry1Ab treatment, valinomycin induced a decrease in IPEC-J2 viability. Two dimensional 
differential in-gel electrophoresis was performed on the cell proteins. Only three proteins were 
differentially expressed. The functions of these proteins were associated with responses to stress. The 
up-regulation of heat shock protein Hsp70 was verified by Western blotting as well as by enzyme-
linked immunosorbent assay and may be related to a protective function. 
 
The present study shows that cultured porcine gastrointestinal cells can tolerate Cry1Ab even in a dose 
range that greatly exceeds any amount that may accumulate in the gastrointestinal tract of pigs. No 
influence on viability of IPEC-J2 cells was found using a screening with different assays including 
real-time monitoring of cell viability (Bondzio et al 2013). Consistent with a previously published 
studies in fish fed maize MON810 [Sagstad et al; 2007], the proteomic data at 24 h were indicative of 
a mild stress response to Cry1Ab. 
 
According to the authors long-term investigations are needed to determine whether increased Hsp70 
expression is only a transient short-term adaptive response to Cry1Ab or may be the cause of further 
unintended side effects of this protein. 
 
Test for possible toxic potential of Cry1Ab on human culture kidney cells 
Mesnage et al. (2012) performed in vitro testing on human culture kidney cells (HEK293) with 
Cry1Ab- and Cry1Ac protein. Time- and dose depenfield effects of relatively high concentrations of 
Cry1Ab on viability of HEK293 cells, respiration inhibition and plasma membrane alterations, were 
detected.When treating the cells with 100 ppm of Cry1Ab the mitochondrial succinate dehydrogenase 
activity was decreased by 11%. Lower doses were tested from 10 ppb to 10 ppm, but significant 
effects were not observed. The adenylate kinase (AK) activity, when released in the medium, reveals 
possible membrane alterations. A Cry1Ab concentration of 100 ppm increased AK leakage in the 
medium 2-fold, revealing plasma membrane alterations. Lower doses were tested from 10 ppb to 10 
ppm, but significant effects were not observed. Mesnage et al. argue that modified Bt toxins are not 
inert on non-target human cells, and that they can present combined side effects with other residues of 
pesticides specific to GM plants. 
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PAT 
The pat gene was originally obtained from Streptomyces viridochromogenes strain Tü494 which has 
no known toxic or pathogenic potential. The PAT protein is enzymatically active but it has high 
substrate specificity to the active ingredient L-phosphinothricin (L-PPT) of glufosinate-ammonium. 
The PAT protein has already been found safe to human health during the assessment of glufosinate-
ammonium tolerant maize (OECD 1999). 
 
4.3.2 Acute toxicity testing 
 
Acute oral exposure of PAT protein in rodents  
Syngenta has rights for citing the acute oral toxicity PAT study on mice conducted by Monsanto. The 
acute oral study was conducted in compliance with EPA Guidelines no. 81-1, and with the following 
good laboratory standards: US Environ. Protection agency FIFRA: Good laboratory standards, 40 CFR 
160 and 40 CFR 158, Japan Minisry of Agric., Forestry and Fisheries, Notf. No. 59 Noshan 3850, 
Director –General of Agricultural Production Bureau, August 1984 and OECD Principles of GLP, 
Annex 2, C(81)30. 
 
PAT Microbial Protein (FL), which was 51% pure microbial protein, was evaluated for acute oral 
toxicity. Group I animals (five male and five female Harlan Sprague Dawley (HSD:ICR) mice 
received 5050 mg/kg ( 51 % pure) of the test material as a 26% w/v suspension in aqueous 2% 
carboxymethylcellulose (CMC), group II (5 males and 5 females) received heath inactivated PAT (52 
% pure) and group III received 19.42 ml/kg bw doses of 2 % CMC only. Parameters evaluated during 
the two-week observation period included body weights and detailed clinical observation. All animals 
were examined for gross pathological changes. One male in Groupe I died during the study. Necropsy 
finding in the animal that died on test pertained to material logged in the esophagus. The ifieldity of 
the material blocking the esophagus was not determined. There were no treatment-related clinical 
observations in the rest of the mice. There were no gross pathological lesions for any other animal in 
the study. Under the condition of this study, the acute oral LD50 of PAT Microbial protein in male and 
female HSD:ICR mice was greater than 2575 mg/kg bw. 
Acute oral exposure of Cry1Ab protein in rodents 
An acute oral toxicity study was performed with the Cry1Ab protein in mice. An acute oral study was 
considered appropriate since toxic proteins are only known to exert acute effects. The Cry1Ab protein 
was administered orally by gavage to three groups of ten male and female mice; additionally, one 
group of mice was dosed with a vehicle control lacking the Cry1Ab the protein. The targeted doses of 
Cry1Ab protein administered to mice were 0, 400, 1000, and 4000 mg/kg. A mice control group was 
dosed with Bovine serum albumin (BSA) at 4000 mg/kg. At the time of sacrifice, 7 days after dosing, 
there were no statistically significant differences in mortality, body weights, cumulative body weight 
or total food consumption between the BSA control groups and Cry1Ab protein-treated groups. 
Results from this study demonstrated that the Cry1Ab protein is not acutely toxic to mammals. 
 
The acute oral toxicity test performed on mice did not indicate toxic effects of E. coli produced 
CryAb1 and PAT protein. However, acute tests do not provide enough information to conclude on 
possible adverse health effects of maize Bt11. In whole food the concentrations of the protein is low 
and acute toxic effects in humans and animals will most probably be negligible. Acute toxicity testing 
of the newly expressed protein is of little additional value to the risk assessment of the repeated human 
and animal consumption of food and feed derived from GM plants and is therefore not taken into 
account in this risk assessment. EFSA discourages the use of acute studies in risk assessments of 
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4.3.3 Repeated dose toxicity testing 
 
14-day oral toxicity study of PAT protein in rats 
Bayer Crop Sciences has performed a sub-chronic oral toxicity study of the PAT-protein in rats 
(Pfister et al. 1996). The study was performed in accordance with the principles of Good Laboratory of 
O.E.C.D. (Organization for Economic Cooperation and Development) and Principles of Good 
Laboratory Practice, 1992. Good Laboratory Practice (GLP) in Switzerland, Procedures and 
Principles, March 1986 and the Japanese Ministry of Agriculture, Forestry and Fisheries: On Good 
Laboratory Practice Standards for Toxicological Studies on Agricultural Chemicals, Agricultural 
Production Bureau, 59 NohSan Notification Number 3850, August 10, 1984. Test guidelines: The 
study procedures mostly conform to OECD Guidelines for Testing of Chemicals, number 407 
"Repeated Dose 28-day Oral Toxicity Study in Rofields", adopted by the Council on July 27, 1995.  
 
The study comprised four groups of five male and five female Wistar rats in each group. The rats in 
group 1 received a standard diet without PAT protein, whereas rats in group 2, 3 and 4 received diets 
with the inclusion of PAT and/or soybean protein: group 1 (standard diet), group 2 (0.5 % PAT + 4.5 
% soybean), group 3 (5 % PAT), group 4 (5 % soybean), for a period of 14 days. According to the 
OECD guidelines the duration of exposure should normally be 28 days although a 14-day study may 
be appropriate under certain circumstances; justification for use of a 14-day exposure period should be 
provided. The duration of this repeated dose oral toxicity study was 14-days. No justification for using 
14-days has been found in the dossier from the applicant. 
 
The mean intake of PAT-protein in group 2 over the treatment period was 712 mg/kg body weight/day 
for males and 703 mg/kg body weight/day for females. In group 3 the mean intake of PAT-protein was 
7965 mg/kg body weight/day for males and 7619 mg/kg body weight/day for females. 
 
The results showed no unscheduled deaths or clinical signs. Food consumption and body weights were 
unaffected by treatment. No treatment-related changes were seen in haematology or urinalysis 
parameters. Organ weight data, macroscopical and microscopical findings did not distinguish treated 
groups from controls. 
 
The only changes which might be attributed to treatment were observed in clinical biochemistry 
parameters. They consisted of a slightly lower glucose level in males of group 4, slightly higher total 
cholesterol and phospholipid levels in males of groups 2, 3 and 4 and slightly higher triglyceride levels 
in females of group 4 when compared with rats of group 1. Animals of group 4 received no PAT-
protein but - with respect to the protein content - a diet most similar to that of groups 2 and 3. The 
changes mentioned above were considered to reflect differences in the dietary composition and not 
related to the PAT protein itself. Further, comparing the increased total cholesterol and phospholipid 
levels between group 3 (5 % PAT) and group 4 (5 % soybean) they were found to be within similar 
range, which may suggest a similar nutritional value of the proteins. 
 
28-day toxicity study in F344 male rats with impaired gastrointestinal function and gut damage, 
administered Cry1Ab protein 
The study comprised four groups of eight male F344 rats in each group (Onose et al. 2008). In the 
control group rats were fed basal diet alone. The other rats were divided a Bt –group fed 10 ppm 
Cry1Ab-protein in feed, a GI-group with impaired gastrointestinal function and gut damage induced 
by treatment with famotidine and indomethacin and a GI + Bt-group. During the experimental period, 
general condition was checked daily, and body weights and food consumption were recorded every 
week. 
 
The concentration for the Bt dosage was selected based on the content of the Cry1Ab-protein in Bt 
maize (Betz et al. 2000), assuming that all the food consumed by the animals was Bt maize. 
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At the end of the experiment, all animals were fasted overnight, anesthetized with ether and 
euthanized by exsanguination. Blood samples were collected from the abdominal aorta. The blood was 
applied for hematology and serum biochemistry. The red blood cell count (RBC), hemoglobin 
concentration (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular 
hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelet count (PLT) and 
white blood cell count (WBC) were determined with an automatic hematology analyzer (K-4500, 
Sysmex, Hyogo, Japan). Differential leukocyte counts and the reticulocyte count were obtained with 
an automatic blood cell analyzer (Microx HEG-120A, Tateishi Electronic, Tokyo, Japan). For serum 
biochemistry, total protein (TP), albumin (Alb), albumin/globulin ratio (A/G), total bilirubine (T-Bil.), 
triglycerides (TG), total cholesterol (T-Cho), blood urea nitrogen (BUN), creatinine (CRE), aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), cglutamyl 
transpeptidase (c-GTP), calcium (Ca), inorganic phosphorus (IP), sodium (Na), chloride (Cl) and 
potassium (K) were measured at the medical laboratory SRL, Inc. (Tokyo, Japan). The medical 
laboratory SRL, Inc. was certified by the College of American Pathologists. 
 
All animals were subjected to a complete necropsy, and the brain, thymus, lungs, heart, spleen, liver, 
adrenals, kidneys and testes were resected and weighed. These organs and the following organs and 
tissues were fixed in 10% neutral buffered formalin and paraffin-embedded sections were cut and 
stained with hematoxylin and eosin (HE) for histopathological examination: skin, mammary gland, 
sternum with marrow, femur with marrow, submandibular and mesenteric lymph nodes, salivary 
glands, aorta, trachea, tongue, esophagus, stomach, small and large intestines, pancreas, urinary 
bladder, epididymides, seminal vesicles, prostate, bulbourethral gland, pituitary, thyroids, 
parathyroids, spinal cord, trigeminal nerve, sciatic nerve, nasal cavity, Harderian gland, eyes and thigh 
muscle. 
 
 The twenty-eight-day study in rats showed no adverse effects that can be attributed to diet containing 
Cry1Ab. The administration of diet containing Cry1Ab protein (10 ppm Cry1Ab) had no significant 
effect on any physiological or biochemical parameter, except a lower level of AST in the serum of 
animals fed such maize, when compared with control. However, no changes in organ weights or histo-
pathological changes were observed in organs like heart, liver, and kidneys. Also, serum AST levels 
are usually elevated with tissue injury, but the interpretation of relatively small changes in AST in 
toxicology studies should be done carefully, since the range of variation of this parameter can be broad 
in healthy animals. The decrease of AST in this experiment, therefore, is not considered to be 
toxicologically significant. 
 
4.4 Toxicological assessment of the whole GM food/feed  
42-day feeding study on broiler chickens 
The wholesomeness and safety of the Bt11 maize has been shown in a 42-day feeding study using 
broiler chickens. A poultry feeding study was conducted to confirm the nutritional equivalence of the 
Bt11 maize with its non-GM commercial maize equivalent (Brake et al. 2003). Broilers were fed over 
a 42-day period.  
 
Four kinds of maize grain were used in this study:  
(1) grain from the Bt-expressing field maize hybrid N7070Bt, 
(2) grain from the N7070Bt hybrid that had been sprayed with Liberty brand herbicide 
(glufosinate) according to manufacturer's instructions (N7070Bt + Liberty), 
(3) grain from standard N7070 (non-Bt isoline of N7070Bt) grain,  
(4) grain from North Carolina grown the 2000 growing season (NC2000).  
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Poultry studies are considered to be very useful because they utilize a fast growing organism that can 
eat a high percentage of maize in the diet, thus, it is very sensitive to potentially toxic effects of dietary 
components (OECD 2003).  
At 41 day of the experiment, there was a sudden and extreme increase in ambient temperature and 
humidity. The heat index exceeded 43°C during the afternoon, and birds began to die. All mortalities 
were weighed as quickly as possible, and on the morning of 42 day, the decision was made to 
terminate the growth performance portion of the experiment by weighing all live birds and total feed 
consumed. For completeness, BW of live and dead birds are presented; however, group differences 
were minor and unimportant. Access to feed was limited on 42 and 43 day of the experiment to allow 
broilers to lose body heat. After the ambient heat stress subsided, the broilers were returned to full 
feed for 44 day through 47 day of the experiment prior to processing. 
 
The results of the study show that there were no significant differences in percentage survivors for 
birds that received the two transgenic maize diets and those that received the N7070 isoline and 
commercial NC2000 maize diets on an overall basis at any age. 
 
However, there were significant differences due to sex, with males exhibiting higher mortality during 
the finisher phase (35 to 42 d) and cumulatively (0 to 42 day). This should be expected in extremely 
hot weather conditions as males are well known to be more susceptible to heat stress. There was a 
significant interaction of sex and maize source for the combined starter-grower periods (0 to 35 day) 
due to some erratic mortality during the grower period (21 to 35 day) that was not evifield on a 
cumulative basis. 
 
According to the authors this interaction did not follow any logical or explainable pattern and probably 
represents chance occurrences. 
The diets prepared with transgenic maize did not have any adverse effects on performance of broiler 
chickens when compared to diets prepared with nontransgenic (isogenic) control and commercial 
maize. Only minor differences were found due to maize source; performance was poorer for birds fed 
the commercial NC2000 maize diets. 
 
According to the applicant this study shows that Bt11 maize is nutritionally equivalent to non-GM 
maize. These findings also provide further confirmation of the safety of the proteins Cry1Ab and PAT 
expressed in the Bt11 maize. The applicant concludes that the Bt11 maize is nutritionally equivalent 
to, and as safe as, non-GM commercial maize.  
 
90-day feeding study in calves 
Twelve healthy four-month-old cross-breed calves (Japanese Black × Holstein) were fed 43.3% Bt11 
or 43.3% non-genetically modified isoline maize grain as dry matter for 90 days, according to the 
feeding experiment procedure for safety assessment of feeds recommended by the Ministry of 
Agriculture, Forestry and Fisheries of Japan (Shimada et al. 2006c). 
 
At the end of the experiment, tissues from the liver, spleen, kidney, mesenteric lymph nodes, and 
musculus longissimus were sampled after slaughter. These tissue samples were examined 
histopathologically and measured for hematological and biochemical parameters, i.e. red blood cells, 
white blood cells, hematocrit, hemoglobin, aspartate aminotransferase, γ-glutamyltransferase, alkaline 
phosphatase, total-bilirubin, total protein, albumin, total cholesterol, triacylglycerol, blood urea 
nitrogen, creatinine, calcium, inorganic phosphorus, magnesium, glucose, sodium, potassium, and 
chlorine in peripheral blood and ruminal pH, volatile fatty acid, lactic acid, ammonia nitrogen, and 
free lipopolysaccharides in rumen juice. 
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No significant gross or histopathological lesions and no discernible clinical, hematological, 
biochemical, or ruminal abnormalities were found in calves fed Bt11 maize as compared with control 
calves fed non-Bt maize. 
 
28-day feeding study in pigs 
Ten castrated pigs weighing 42 kg (Large White/Duroc cross) were fed diets containing 60% Bt11 or 
non-Bt isoline maize grain for four weeks (Shimada et al. 2008). At the end of the experiment, the 
liver, spleen, kidney, heart, lung, lymph nodes, thymus, tonsils, stomach, duodenum, pancreas, 
jejunum, ileum, ileocecum, cecum, colon, rectum, and spinal cord were sampled after slaughter. These 
tissue samples were examined histopathologically. There were no significant differences in 
histopathological observation between Bt and control groups. 
 
28-day feeding study in poultry 
Ten one-week-old male White Leghorns were fed diets containing 61.22% of Bt11 or non-Bt isoline 
maize for four weeks (Shimada et al. 2008).  
 
At the end of the experiment, the liver, spleen, kidney, heart, lung, thymus, thyroid, glandular 
stomach, gizzard, duodenum, jejunoileum, and spinal cord were sampled after slaughter. These tissue 
samples were examined histopathologically. No significant differences in histopathological 
observation were found between Bt and control groups. 
 
Mice reproduction toxicity study over five generation. 
A long term performance of multi-generations or life span was assessed using genetically modified 
(GM) insect-resistant Bt11 maize (Haryu et al. 2009). Diet containing 68% of GM Bt11 or non-Bt 
isoline with sufficient nutrient composition was fed to male and female ICR mice through 5 
generations. The study was performed according to OECD test guideline408 Repeated dose 90-day 
oral toxicity study in rofields(OECD 1998), OECD test guideline 43 Guidance Document On 
Mammalian Reproductive Toxicity Testing and Assessment (OECD 2008) and OECD Environmental 
Health and Safety Publications: Considerations for the Safety Assessment of Animal Feedstuffs 
Derived from Genetically Modified Plants (OECD 2003). 
 
Parent generation (F0) consisted of 31 females and 16 males. They were cross-bred at the age of 60-70 
days. The rate of vaginal plug formation, delivery rate and period, number of fetuses, sex ratio of 
fetuses, weaning period and feed intake and individual body weight were recorded. F1 mice were bred 
in the same manner to generate the follow-up generations. One day before delivery of F4 fetuses, the 
pregnant mice were sacrificed to count the number of fetuses, determine possible abnormalities as well 
as size and weight of placenta and ovaries. 
 
The results of growth, mating, gestation, milking periods, reproduction and life span were not different 
between the GM Bt11 and non-Bt fed groups. The percentage of embryonic death, litter size, newborn 
sex ratio and body weight (21-60 days after birth) were not different between these groups. The life 
span of the third-generation mice did not differ over 1,072 days of observation. In addition, there was 
a tendency for a weight decrease among each group as the generations progressed, but there was no 
significant difference in performance among each group in each generation of mice. There was no 
relevant difference in growth, reproduction performance and life span between the GM and control 
groups. (Haryu et al. (2009).  
 
Short term and multigenerational mouse studies. 
A short term and a multigenerational study were performed on mice (Brake et al. 2004). Bt maize 
(Bt11 (38PO6)) was studied with mouse testes as a sensitive biomonitor of potential toxic effects. 
Pregnant mice were fed a Bt maize (38PO6) or a non-transgenic (conventional maize 38PO5) diet 
during gestation and lactation. 
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Short term study. 
Bt or conventional maize diets were fed to 20 randomly selected female mice (10 for each diet). 
Following breeding, gestation, and parturition, three male progeny of the same age (by day) were 
chosen at random for each of six time points, 8, 16, 26, 32, 63, and 87 days after birth. Time points 
were selected to show the various stages of cellular proliferation and differentiation that occur during 
the development of the testes and ongoing cycles of spermatogenesis. The relative percent of testicular 
cell populations reflects the kinetics of the developing testes.  
 
After they were weaned, young male mice were maintained on the respective diets. At 8, 16, 26, 32, 
63, and 87 days after birth, three male mice and an adult reference mouse were killed, the testes were 
surgically removed, and the percentage of germ cell populations was measured by flow cytometry. No 
differences between conventional and Bt maize-fed mice were seen at 87 days after birth as ongoing 
cycles of spermatogenesis ensued. 
 
General health parameters of mice fed the Bt maize diet showed no differences in body weight through 
day 63 (p < 0.1074) as compared to those on the conventional maize diet suggesting that the Bt maize 
diet caused no negative impact on body growth. However, the 87 day old conventional diet mice were 
fatter. However, the 63 day old mice were the exact opposite (Bt maize diet weighed more), and this 
was attributed to individual eating behavior after adulthood is achieved. Average litter sizes in the two 
groups were similar (Bt = 7.2 ± 1.0, n = 9; conventional = 7.3 ± 1.0, n = 9). 
 
Multigenerational studies. 
Multigenerational studies were conducted in the same manner. Transgenic or conventional diets were 
fed to 16 randomly selected male and female mice (two of each sex and strain for each diet). 
Following breeding, gestation, parturition, and weaning, six female and three male 2nd generation 
progeny of each strain and diet were randomly selected for growth, development, and breeding to 
obtain the 3rd generation. Surplus mice from each generation were culled. When all 3rd generation 
mice were at least 6 weeks old, six C57Bl/6J females and three C3H/HeJ males were randomly chosen 
and bred to obtain 4th generation cross-bred progeny. Three male progeny of the same age (by day) 
were chosen at random for each of five time points. Time points and sampling followed the same 
procedure as the subchronic study, except that the extended adult time point at 87 days postpartum 
was deleted. 
 
General Health Parameters. Mean body weights showed differences between conventional and 
transgenic maize-fed mice at 26 (p < 0.0001) and 63 (p < 0.0100) days (Figure 3B). At both time 
periods, the Bt maize-fed mice were heavier than the control mice. Mean body weight results suggest 
that ingestion of a Bt maize diet resulted in no multigenerational impacts on animal growth. Average 
litter sizes were comparable (Bt = 8.2 ± 1.9, n = 5; conventional = 6.6 ± 2.1, n = 5). 
 
There were no apparent differences in percentages of testicular cell populations (haploid, diploid, and 
tetraploid) between the mice fed the Bt maize diet and those fed the conventional diet. Because of the 
high rate of cell proliferation and extensive differentiation that makes testicular germ cells highly 
susceptible to some toxic agents, it was concluded that the Bt maize diet had no measurable or 
observable effect on fetal, postnatal, pubertal, or adult testicular development. If data from this study 
were extrapolated to humans, Bt maize is not harmful to human reproductive development. 
 
Nakajima et al. (2007) characterised the IgE antibodies of human sera by enzyme-linked 
immunosorbent assay (ELISA) and immunoblotting. For the ELISA assay, a soluble form of the 
Cry1Ab protein, purified from E. coli transformed with a DNA sequence from maize Bt11, was used 
as antigen. All tested sera from patients allergic to major food allergens did not contain IgE antibodies 
directed against Cry1Ab. 
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Nakasuji et al. (2008) monitored the presence of common enterobacterial genes, a ubiquitous plant 
chloroplast gene, maize intrinsic zein (Ze1) and recombinant cry1Ab gene in the gastrointestinal 
contents, peripheral blood mononuclear cells and visceral organs of mice and their progeny fed with 
maize Bt11. The enterobacterial and chloroplast genes were detected inconsistently in peripheral blood 
mononclear cells, visceral organs, milk or liver of suckling mice, while Ze1 and cry1Ab were not 
detected. These results suggest that feed-derived enterobacterial and plant DNAs were incompletely 
degraded in the gastrointestinal tract, and part of them were absorbed into organs or milk as a source 
of transfer into suckling mice, but the cry1Ab gene was not transferred. 
 
14-day feeding study in high producing dairy cows 
Three groups of 4 dairy cows were fed fresh chopped whole plant maize (ca. 22.7 kg of dry matter per 
animal and per day) of either Bt11 maize, another insect tolerant transgenic maize (Bt 176) and the 
non-transgenic, near isogenic counterpart of Event 176. Both Bt11 maize and Bt 176 have been 
modified with the Cry1Ab and PAT proteins. Bt 176 derived from plants contained intermediate 
levels, and plants from the Bt11 maize variety contained relatively high levels of Cry1Ab protein. 
While the aim of this study was to determine whether transfer of Cry1Ab and PAT to milk from cows 
fed transgenic maize would occur, it also provides information on animal performance. Milk 
production, feed intake, milk composition, and udder health were similar for all study groups. Cry1Ab 
and PAT proteins could not be detected in milk of cows fed the genetically modified maize lines. 
 
Cry1Ab protein and DNA fragments of the cry1Ab gene in the gastrointestinal content of animals fed 
Bt11 maize. 
Chowdhury et al. (2003a) examined the presence of maize intrinsic and recombinant cry1Ab gene by 
PCR, and the Cry1Ab protein by immunological tests in the gastrointestinal contents of five 
genetically modified maize Bt11-fed and five non-genetically modified maize-fed pigs. 
 
Fragments of maize zein (242 bp), invertase (226 bp) and of ribulose-1,5-bisphosphate carboxylase/ 
oxygenase genes (1,028 bp) were detected in the gastrointestinal contents of both Bt11 and 
nongenetically modified maize-fed pigs. Fragments of recombinant cry1Ab gene (110 bp and 437 bp) 
were detected in the gastrointestinal contents of the Bt11-fed pigs but not in the control pigs. Neither 
maize intrinsic nor cry1Ab gene fragments were detected in the peripheral blood by PCR. The 
gastrointestinal contents were positive for Cry1Ab protein by ELISA, immune chromatography, and 
immunoblot; however, these methods did not work for blood and precluded conclusions about any 
potential absorption of the protein. These results suggest that ingested maize DNA and Cry1Ab 
protein were not totally degraded in the gastrointestinal tract, as shown by their presence in a form 
detectable by PCR or immunological tests. 
Chowdhury et al (2003b) examined the fate of insecticidal Cry1Ab protein in the gastrointestinal (GI) 
contents and visceral organs of calves fed insect-resistant genetically modified maize Bt11. Twelve 
cross-breed (Japanese black x Holstein) calves were fed either Bt11 or non-genetically modified 
isoline maize for 90 days. Peripheral blood, rumen juice and feces were collected fortnightly, and GI 
contents and visceral organs were collected at slaughter at the end of the experiment. Samples were 
checked for Cry1Ab protein by immunological methods, and visceral organs were examined 
pathologically. Trace amounts of Cry1Ab protein were detected in the GI contents but not in the liver, 
spleen, kidney, muscle or mesenteric lymph nodes. No lesions were observed pathologically. Cry1Ab 
protein in the feces was degraded quickly at atmospheric temperature. These results suggested that 
only a trace amount of Cry1Ab protein survived passage through the GI tract but was not transferred 
to liver, spleen, kidney, lymph nodes or muscles. 
 
Chowdhury et al (2004) examined the presence of maize intrinsic and recombinant cry1Ab genes in 
the gastrointestinal (GI) contents, peripheral blood mononuclear cells (PBMC), and visceral organs of 
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calves fed genetically modified Bt11 maize.during a subchronic 90-day performance study. Samples 
were collected from six Japanese Black/Holstein calves fed Bt11 maize and from six calves fed non-Bt 
maize. DNA-fragments of maize zein (Ze1), invertase, chloroplast, and cry1Ab measured by PCR 
were detected inconsistently in the rumen fluid and rectal contents 5 and 18 h after feeding. The 
chloroplast DNA fragments of ribulose-1,5-bisphosphate carboxylase/oxygenase and tRNA were 
detected inconsistently in the PBMC, the visceral organs, and the longissimus muscle, while the 
cry1Ab gene was never detected in PBMC or in the visceral organs. These results suggest that feed-
derived maize DNA was mostly degraded in the GI tract but that fragmented DNA was detectable in 
the GI contents as a possible source of transfer to calf tissues. These results also suggest that the 
recombinant cry1Ab genes were not transferred to the PBMC and tissues of calves fed Bt11 maize. 
The applicant has provided several animal studies; some of these are taken into account in the 
evaluation. However, other studies are either performed with only dose or with too short exposure 
time. 
 
4.5 Allergenicity assessment 
 
Most food allergies are mediated by Immunoglobulin E (IgE, type-I reactions). The strategies used 
when assessing the potential allergenic risk focuses on the characterisation of the source of the 
recombinant protein, the potential of the newly expressed protein to induce sensitisation, or to elicit 
allergic reactions in already sensitised individuals and whether the transformation may have altered 
the allergenic properties of the modified food. A weight-of-evidence approach is recommended, taking 
into account all of the information obtained with various test methods, since no single experimental 
method yields decisive evidence for allergenicity (EFSA 2010).  
 
Most of the major food and respiratory IgE-allergens have been identified and cloned, and their 
protein sequences incorporated into various databases. As a result, novel proteins can be routinely 
screened for amino acid sequence homology and structural similarity to known human IgE-allergens 
using an array of bioinformatics tools. Sequence homology searches comparing the structure of novel 
proteins to known IgE-allergens in a database are conducted using various algorithms such as FASTA 
to predict overall structural similarities. According to FAO/WHO (2001) in cases where a novel 
protein and a known IgE-allergen have more than 35% ifieldity over a segment of 80 or greater amino 
acids, IgE cross-reactivity between the novel protein and the allergen should be considered a 
possibility. 
 
4.5.1 Assessment of IgE mediated allergenicity of the newly expressed protein 
 
A weighted risk analysis based on the decision tree approach has been performed by the applicant. The 
individual steps of this analysis starts by analyzing the primary amino sequence of the novel protein 
and looking for similarity with sequences to known allergens, followed by specific or targeted serum 
screens for IgE cross-reactions to known allergens, digestibility studies of the proteins in simulated 
gastric and/or intestinal fluids, and animal studies (FAO/WHO, 2001, Codex Alimentarius, 2003, 
König et al., 2004, Poulsen 2004). 
These assessments have previously been described by the applicant for Cry1Ab and PAT, and were 
based on the following aspects:  
 
Cry1Ab and PAT 
i) The sources of the transgene genes: B. thuringiensis (cry-genes) and S. viridochromogenes 
(pat) have no history of causing IgE-mediated allergy 
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ii) History of safe use of Cry proteins as microbial pesticides (US EPA, 1998), no indications of 
Cry proteins originating from Bacillus thuringiensis having harmful effects on the health of 
humans and animals (US EPA, 1996).  
iii) The PAT protein has been subjected to previous safety assessments for genetically modified 
plants and found to have no IgE-mediated allergenic potential  
iv) The PAT protein have no homology to known toxins or allergenic proteins  
v) The microbially produced Cry1Ab and PAT proteins were rapid degraded in simulated gastric 
fluids in vitro. No degradation assay in gastrointestinal fluids has been performed by the 
applicant. 
vi) PAT and Cry1Ab does not resemble any characteristics of known IgE-allergens, and no 
significant homologies between the amino acid sequences of the PAT and Cry1Ab proteins 
and IgE-allergenic proteins have been found (Fard et al, 2013, Kim et al, 2010, Randhawa et al 
2011, Meyer, 1999, US EPA, 2010).  
vii) The PAT and Cry1Ab protein is not glycosylated (Raybold et al, 2013, US EPA, 2010) 
viii) Cry1Ab and PAT are considered heat labile  (US EPA 2010) 
 
4.5.2 Assessment of the IgE-mediated allergenicity of the whole GM plant 
 
Allergenicity of the maize Bt11 could be increased as an unintended effect of the random insertion of 
the transgene in the genome of the recipient, e.g. through qualitative or quantitative modifications of 
the expression of endogenous proteins. However, given that no biologically relevant agronomic or 
compositional changes have been identified in field maize Bt11 or sweet maize Bt11with the 
exception of the introduced traits, no increased allergenicity is anticipated for maizeBt11. Moreover, 
maize is not considered a common allergenic food.  
 
4.5.3 Assessment of the IgE-mediated allergenicity of proteins from the GM plant 
 
It is the opinion of the VKM GMO Panel that a possible over-expression of any endogenous protein, 
which is not known to be allergenic, in maize Bt11 would be unlikely to alter the overall allergenicity 




According to the EFSA Opinion on the assessment of allergenicity of GM plants and microorganisms 
and derived food and feed (EFSA 2010) adjuvants are substances that, when co-administered with an 
antigen increase the immune response to the antigen and therefore might increase the allergic 
response. In cases when known functional aspects of the newly expressed protein or structural 
similarity to known strong adjuvants may indicate possible adjuvant activity, the possible role of these 
proteins as adjuvants should be considered. As for allergens, interactions with other constituents of the 
food matrix and/or processing may alter the structure and bioavailability of an adjuvant and thus 
modify its biological activity. 
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Only two of the ~ 10 Cry proteins that are currently used in genetically modified plants, Cry1Ab and 
Cry1Ac, have been studied experimentally regarding adjuvant effects. To the knowledge of the VKM 
GMO Panel, adjuvant effects have not been investigated for the other Cry proteins normally used in 
GM plants, or other groups of Cry proteins.  
 
Studies with immunological mapping of the systemic and mucosal immune responses to Cry1Ac have 
shown that mice produce both systemic IgM and IgG and secretory IgA following intraperitonal (i.p.), 
intragastric (i.g.) or intranasal (i.n.) immunisation, and that the adjuvant effects of Cry1Ac is 
comparable to that of cholera toxin (CT) (Guerrero et al., 2004; Vazquez-Padron et al., 1999a, b; 
2000; Moreno-Fierros et al., 2003). The adjuvant effect of CT is thus a relevant basis for comparison 
in a risk assessment of Cry1Ac. It is uncertain whether this applies to the same extent to other Cry 
proteins. A possible immunogenicity and adjuvanticity of Cry proteins has been considered by EFSA 
and VKM (EFSA 2009, VKM 2012). 
 
“Bystander sensitisation” 
"Bystander sensitisation” can occur when an adjuvant in food, or an immune response against a food 
antigen, results in an increased permeability of the intestinal epithelium for other components in food. 
Traditionally it was assumed that the epithelial cells of the intestine were permanently "glued 
together" by the so-called "tight junctions". Studies have however shown that these complex protein 
structures are dynamic and that they can be opened up by different stimuli. 
Both in vitro and in vivo experiments have demonstrated that when an IgG response which can result 
in a complement activation (among other) is not balanced by an IgA response, the epithelial barrier 
can be opened and unwanted proteins are able to enter the body (bystander-penetration) and lead to 
allergic sensitisation (Brandtzaeg & Tolo 1977;  Lim & Rowley 1982). 
 
Additional information can be found in the report by VKM on Cry-proteins and adjuvanticity: “Health 
risk assessment of the adjuvant effects of Cry proteins from genetically modified plants used in food 
and fodder” (VKM 2012). 
 
4.6 Nutritional assessment of GM food/feed 
 
Compositional analyses of maize Bt11 and sweet maize Bt11 indicate nutritional equivalence to the 
non-GM control maize with comparable genetic background and to the published range of values in 
the literature. The nutritional equivalence between Bt11 maize and non-GM control maize has been 
further shown by the results of a poultry feeding study, feeding study in dairy cows, beef steers, pigs 
and calves. 
 
4.6.1 Intake information/exposure assessment 
 
Net import of maize staple, e.g. flour, starch and mixed products, in Norway in 2007 was 7600 tons, 
corresponding to 4.4 g dry weight/person/day or an estimated daily energy intake for adults to be 0.6 
% (Vikse 2009). The estimated median daily intake of sweet maize is 3.25 g/day, with a 97,5 % 
percentile of 17.5 g/day. The production of maize porridge for children in 2007 was about 37.5 tons, 
corresponding to a daily intake of 1.7 g/day or an estimated daily energy intake to be 0.6 % for a 6 
month child (Vikse 2009).  
 
The comparable composition and nutritional value of the maize, together with the results of the 
assessment of dietary intake and nutritional impact, indicate that food products derived from Bt11 
maize are nutritionally equivalent to food products derived from commercial maize. Hence, 
anticipated dietary intake is not expected to change.  
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Since  most foods and foodstuffs from maize are derived from field maize grains, an estimated 
maximum daily intake for a Norwegian adult of Cry1Ab protein from maize staple is calculated to be  
8.8 µg, based on grain dry weight, and the estimated maximum daily intake of Cry1Ab from sweet 
maize is calculated to be 67 µg, based on a daily intake of 17.5 g fresh sweet maize/day (97.5 % 
percentile) These levels are several orders of magnitude below the levels shown to have no effect in 
laboratory toxicology testing. Also, these levels are considerably below the proposed threshold of 
toxicological concern (TTC) level of 1800 µg/person/day (Class 1, oral exposure) for chemicals 
considered to have a low potential for toxicity based on metabolism and mechanistic data (Vermeire et 
al., 2010). Transgenic proteins produced by genetically modified plants are generally not considered 
toxic to humans.  
 
The VKM GMO Panel notes that farm (production) animals e.g. pigs and poultry often are fed diets 
with a substantial inclusion of unprocessed maize grain, and that the exposure to transgenic proteins 
from maize Bt11 may be higher for these animals. 
 
This dietary exposure assessment is very conservative as it assumes that all maize consumed comes 
from maize Bt11 and that the transgenic proteins are not denatured by processing.  
 
4.6.2 Nutritional assessment of feed derived from the GM plant 
 
Utilization of Bt maize residue and maize silage for growing beef steers and dairy cows. 
a) Utilization of Bt maize residues by grazing beef steers and Bt maize silage and grain by growing 
beef cattle and lactating dairy cows has been reported by Folmer et al. (2002). Sixteen lactating dairy 
cows received diets containing silage of an early- and late-maturing variety of Bt11 maize or a control 
with the corresponding non-transgenic near isogenic maize line during 21-day feeding periods. No 
differences were observed between Bt11 maize and control maize for feed intake, body weight, milk 
production, and milk composition (lactose, protein, fat), as well as ruminal pH and volatile fatty acids. 
In addition no effects either were observed of the transgenic trait on in situ ruminal digestion of 
neutral detergent fibre of maize. 
 
b) The same silages as those used for the dairy cow study were used in a beef cattle study which lasted 
for 101 days. Measurements included feed intake and body weight. Dry matter intake was significantly 
higher in steers fed early- and late-maturing Bt11 maize when compared with those fed diets 
containing non-GM silage. In addition, average daily weight gain in early maturing Bt11 maize-fed 
steers was higher than in control-fed steers, while final body weight and feed efficiency was decreased 
in steers fed late maturing Bt11 maize compared with steers fed control maize. In conclusion, the 
slightly higher dry matter intake was not associated with other effects on performance of beef cattle 
fed Bt11 maize that would be consistent for diets of both Bt11 maize lines. (see Appendix 8.4). 
 
According to the applicant, the maize and derived feed products are substantially equivalent to, 
nutritionally equivalent to and as safe as commercial maize and derived feed products. This is based 
on the compositional analyses comprising proximates, minerals, fatty acids, amino acids, vitamins, 
secondary metabolites and anti-nutrients of forage and grain samples from; nutritional equivalence 





Whole food feeding studies have not indicated any adverse health effects of maize Bt11. These studies 
also indicate that maize Bt11 is nutritionally equivalent to conventional maize. The Cry1Ab and PAT 
proteins do not show sequence resemblance to other known toxins or IgE allergens, nor have they 
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been reported to cause IgE mediated allergic reactions. Some studies have however indicated a 
potential role of Cry-proteins as adjuvants in allergic reactions. 
 
Based on current knowledge, the VKM GMO Panel concludes that maize Bt11 is nutritionally 
equivalent to conventional maize varieties. It is unlikely that the Cry1Ab and PAT proteins will 
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5 Environmental risk assessment 
 
5.1 Unintended effects on plant fitness due to the genetic modification 
 
Maize (Zea mays L.) is an annual plant and member of the grass family Poacea. The species, 
originating from Central America, is highly domesticated and generally unable to survive in the 
environment without management intervention (Eastham & Sweet 2002).  Maize propagates entirely 
by seed produced predominantly by cross-pollination (OECD 2003). In contrast to weedy plants, 
maize has a pistillate inflorescence (ear) with a cob enclosed with husks. Due to the structure of the 
cob, the seeds remain on the cob after ripening and natural dissemination of the grain rarely occurs.  
 
The survival of maize in Europe is limited by a combination of absence of a dormancy phase resulting 
in a short persistence, high temperature requirements for germination, low frost tolerance, low 
competitiveness and susceptibility to plant pathogens, herbivores and climatic conditions (van de Wiel 
et al. 2011). Maize plants cannot survive temperatures below 0ºC for more than 6 to 8 hours after the 
growing point is above ground  (OECD 2003), and in Norway and most of Europe, maize grain and 
seedlings do not survive the winter cold (Gruber et al. 2008). Observations made on cobs, cob 
fragments or isolated grains shed in the field during harvesting indicate that grains may survive and 
overwinter in some regions in Europe, resulting in volunteers in subsequent crops. The occurrence of 
maize volunteers has been reported in Spain and other European regions (e.g. Gruber et al. 2008). 
However, maize volunteers have been shown to grow weakly and flower synchronously with the 
maize crop (Palaudelmás et al. 2009). Cross-pollination values recorded were extremely variable 
among volunteers, most probably due to the loss of hybrid vigour and uniformity. Overall cross-
pollination to adjacent plants was estimated as being low.  
 
Despite cultivation in many countries for centuries, seed-mediated establishment and survival of maize 
outside cultivation or on disturbed land in Europe is rare (BEETLE Report 2009). Maize plants 
occasionally grow in uncultivated fields and by roadsides. However the species is incapable of 
sustained reproduction outside agricultural areas in Europe and is non-invasive of natural habitats 
(Eastham & Sweet 2002; Devos et al. 2009). There are no native or introduced sexually cross-
compatible species in the European flora with which maize can hybridise and form backcross progeny 
(Eastham & Sweet 2002; OECD 2003). The only recipient plants that can be cross-fertilised by maize 
are other cultivated maize cultivars.  
 
It is considered very unlikely that the establishment, spread and survival of maize Bt11 would be 
increased due to the insect resistance and herbicide tolerance traits. The herbicide tolerant trait can 
only be regarded as providing a selective advantage for the GM maize plant where and when 
glufosinate ammonium-based herbicides are applied. Glufosinate ammonium-containing herbicides 
have been withdrawn from the Norwegian market since 2008, and the substance will be phased out in 
the EU in 2017 for reasons of reproductive toxicity. Similarly insect resistance against certain 
lepidopteran pests provides a potential advantage in cultivation of Bt11 under infestation conditions. It 
is considered very unlikely that maize Bt11 plants or their progeny will differ from conventional 
maize cultivars in their ability to survive as volunteers until subsequent seasons, or to establish feral 
populations under European environmental conditions.  
 
Due to the insufficient data provided by the notifier, no conclusions can be made on the agronomic 
behavior and characteristics of the GM maize Bt11 as well as the related phenotypic characteristics 
such as reproduction, dissemination and survivability. There are, however, no indications of altered 
fitness of maize Bt11 relative to its conventional counterpart and the VKM GMO Panel is not aware of 
any scientific reports indicative of increased establishment or spread of maize Bt11, or changes to its 
survivability (including over-wintering), persistence or invasive capacity. Because the general 
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characteristics of maize Bt11 are unchanged, insect resistance, glufosinate tolerance are not likely to 
provide a selective advantage outside of cultivation in Europe. The VKM GMO Panel is of the opinion 
that the likelihood of unintended environmental effects based on establishment and survival of maize 
Bt11 will not differ from that of conventional maize varieties. 
 
5.2  Potential for gene transfer 
 
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic material, 
either through horizontal gene transfer of DNA, or vertical gene flow via pollen or seed dispersal. 
Exposure of microorganisms to transgenic DNA occurs during decomposition of plant material 
remaining in the field after harvest or comes from pollen deposited on cultivated areas or the field 
margins. Transgenic DNA is also a component of a variety of food and feed products derived from 
maize Bt11. This means that micro-organisms in the digestive tract in humans and animals (both 
domesticated animals and other animals feeding on fresh or decaying plant material from the 
transgenic maize line) may be exposed to transgenic DNA. 
 
Maize is the only representative of the genus Zea in Europe, and there are no cross-compatible wild or 
weedy relatives outside cultivation with which maize can hybridise and form backcross progeny 
(Eastham & Sweet 2002; OECD 2003). Vertical gene transfer in maize therefore depends on cross-
pollination with other conventional or organic maize varieties. All maize varieties which are cultivated 
in Europe can interbreed. In addition, unintended admixture/adventitious presences of genetically 
modified material/transgenes in seeds represent a possible way for gene flow between different 
production systems.  
 
5.2.1 Plant to micro-organisms gene transfer 
 
Experimental studies have shown that gene transfer from transgenic plants to bacteria rarely occurs 
under natural conditions and that such transfer depends on the presence of DNA sequence similarity 
between the DNA of the transgenic plant and the DNA of the bacterial recipient (Nielsen et al. 2000; 
De Vries & Wackernagel 2002, reviewed in EFSA 2004, 2009a; Bensasson et al. 2004; VKM 2005b). 
 
Based on established scientific knowledge of the barriers for gene transfer between unrelated species 
and the experimental research on horizontal transfer of genetic material from plants to 
microorganisms, there is today little evidence pointing to a likelihood of random transfer of the 
transgenes present in maize Bt11 to unrelated species such as bacteria.   
 
It is however pointed out that there are limitations in the methodology used in these experimental 
studies (Nielsen & Townsend 2004). Experimental studies of limited scale should be interpreted with 
caution given the scale differences between what can be experimental investigation and commercial 
plant cultivation.  
 
Experiments have been performed to study the stability and uptake of DNA from the intestinal tract in 
mice after M13 DNA was administered orally. The DNA introduced was detected in stool samples up 
to seven hours after feeding. Small amounts (<0.1%) could be traced in the blood vessels for a period 
of maximum 24 hours, and M13 DNA was found in the liver and spleen for up to 24 hours (Schubbert 
et al. 1994). By oral intake of genetically modified soybean it has been shown that DNA is more stable 
in the intestine of persons with colostomy compared to a control group (Netherwood et al. 2004). No 
GM DNA was detected in the faeces from the control group. Rizzi et al. (2012) provides an extensive 
review of the fate of feed-derived DNA in the gastrointestinal system of mammals.  
 
In conclusion, the VKM GMO Panel consider it is unlikely that the introduced gene from maize Bt11 
will transfer and establish in the genome of microorganisms in the environment or in the intestinal 
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tract of humans or animals. In the rare, but theoretically possible case of transfer of the cry1Ab and pat 
genes from Bt11 to soil bacteria, no novel property would be introduced into or expressed in the soil 
microbial communities; as these genes are already present in other bacteria in soil. Therefore, no 
positive selective advantage that would not have been conferred by natural gene transfer between 
bacteria is expected. 
 
5.2.2 Plant to plant gene flow 
 
Considering the intended uses of maize Bt11 (excluding cultivation) and the physical characteristics of 
maize seeds, possible pathways of gene dispersal are grain spillage and dispersal of pollen from 
potential transgenic maize plants originating from accifieldal grain spillage during transport and/or 
processing.  
 
The extent of cross-pollination to other maize cultivars will mainly depend on the scale of accifieldal 
release during transportation and processing, and on successful establishment and subsequent 
flowering of the maize plant. For maize, any vertical gene transfer is limited to other varieties of Zea 
mays plants as populations of sexually compatible wild relatives of maize are not known in Europe 
(OECD 2003). 
 
Survival of maize plants outside cultivation in Europe is mainly limited by a combination of low 
competitiveness, absence of a dormancy phase and susceptibility to plant pathogens, herbivores and 
frost. As for any other maize cultivars, GM maize plants would only survive in subsequent seasons in 
warmer regions of Europe and are not likely to establish feral populations under European 
environmental conditions. In Norway, maize plants from seed spillage occasionally grow on tips, 
waste ground and along roadsides (Lid & Lid 2005). 
 
The flowering of occasional feral GM maize plants origination from accifieldal release during 
transportation and processing is however unlikely to disperse significant amounts of GM maize pollen 
to other maize plants. Field observations performed on maize volunteers after GM maize cultivation in 
Spain revealed that maize volunteers had a low vigour, rarely had cobs and produced pollen that cross-
pollinated neighbour plants only at low levels (Palaudelmás et al. 2009).  
 
As maize Bt11 has no altered survival, multiplication or dissemination characteristics, the VKM GMO 
Panel is of the opinion that the likelihood of unintended environmental effects as a consequence of 
spread of genes from this GM maize in Norway will not differ from that of conventional maize 
varieties. The likelihood of cross-pollination between cultivated maize and the occasional feral maize 
plants resulting from grain spillage is considered extremely low. 
 
5.3 Interactions between the GM plant and target organisms 
 
Genetically modified maize Bt11 was developed to provide protection against a variety of target pests 
of the order Lepidoptera. Protection is achieved through expression in the plant of insecticidal Cry 
protein Cry1Ab, derived from Bacillus thuringiensis, a common soil bacterium. Cry1Ab, encoded by 
the cry1Ab gene, is derived from B. thuringiensis subspecies kurstaki. Two Lepidoptera pests are 
primarily targeted by Bt11;  Ostrinia nubilalis (European corn borer, ECB) and Sesamia nonagrioides  
(Mediterranean corn borer, MCB).  
  
The European corn borer is widely distributed in Europe covering the Iberian Peninsula, Czech 
Republic and Slovakia, southwest of France, northern Italy and the southern regions of Germany and  
Poland. The Mediterranean corn borer is present in the Mediterranean region (Andreadis 2011). There  
are ten reports of O. nubilalis in Norway, restricted to the counties of Vestfold, Telemark, Aust-Agder  
and Vest Agder. Sesamia spp. has not been reported in Norway. There are no reports of O. nubilalis  
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attaining pest status in Norway, and the Plant Clinic (Planteklinikken) at Bioforsk has never received  
samples of this pest or plant material damaged by this pest (K. Ørstad pers. com.). Consequently, there  
are no insecticides authorised or previous applications for registrations of insecticides against this 
herbivore in Norway.  
  
Aphids are the only pests reported on maize in Norway. Studies have shown that aphids are not 
affected by the Cry1Ab protein (Bourguet et al. 2002). Under the development of Bt maize expressing  
Cry1Ab, the noctuid Agrotis ipsilon was tested as a target, but there was little or no effect (Pilcher et 
al. 1997). This species is occasionally a pest in root crops in Norway and it is conceivable that it could  
become a pest of maize.  
 
Considering the intended uses of maize Bt11, excluding cultivation, the environmental exposure is 
limited to exposure through manure and faeces from the gastrointestinal tract mainly of animals fed on 
the GM maize as well as to the accifieldal release into the environment of GM seeds during 
transportation and processing and subsequently to potential occurrence of sporadic feral plants. Thus 
the level of exposure of target organisms to the Cry1Ab protein is likely to be extremely low and of no 
ecological relevance. 
 
5.4 Interactions between the GM plant and non-target organisms (NTOs) 
 
Considering the intended uses of maize stack Bt11, excluding cultivation, the environmental risk 
assessment is concerned with accifieldal release of GM maize viable grains into the environment 
during transportation and processing, and exposure through manure and faeces from the 
gastrointestinal tracts of animals fed the GM maize.  
 
Cry proteins are degraded by enzymatic activity in the gastrointestinal tract, meaning that only very 
low amounts would remain intact to pass out in faeces (e.g. Lutz et al. 2005, Guertler et al. 2008; Paul 
et al. 2010).  There would subsequently, be further degradation of the Cry proteins in the manure and 
faeces due to microbial processes. In addition, there will be further degradation of Cry proteins in soil, 
reducing the possibility for the exposure of potentially sensitive non-target organisms. Although Cry 
proteins bind rapidly on clays and humic substances in the soil and thereby reducing their availability 
to microorganisms for degradation, there is little evidence for the accumulation of Cry proteins from 
GM plants in soil (Icoz & Stotzky 2009). 
 
Data supplied by the applicant indicate that a limited amount of the Cry1Ab protein enters the 
environment due to expression in the grains (mean value of 2.0 µg/g d.w). In addition, the data show 
that at least 99% of microbially produced Cry1Ab1 protein was rapidly degraded in simulated gastric 
fluid.  
 
In conclusion, the VKM GMO Panel considers that the exposure of potentially non-target organisms 
to the binary Cry1Ab protein is likely to be very low and of no ecological relevance. 
 
5.5 Potential interactions with the abiotic environment and biochemical 
cycles 
 
Considering the intended uses of maize Bt11, which exclude cultivation, and the low level of exposure 
to the environment, potential interactions of the GM plant with the abiotic environment and 
biogeochemical cycles were not considered an issue by the VKM GMO Panel. 
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5.6 Post-market environmental monitoring  
 
Directive 2001/18/EC introduces an obligation for applicants to implement monitoring plans, in order 
to trace and ifieldify any direct or indirect, immediate, delayed or unanticipated effects on human 
health or the environment of GMOs as or in products after they have been placed on the market. 
Monitoring plans should be designed according to Annex VII of the Directive. According to Annex 
VII, the objectives of an environmental monitoring plan are 1) to confirm that any assumption 
regarding the occurrence and impact of potential adverse effects of the GMO or its use in the 
environmental risk assessment (ERA) are correct, and (2) to ifieldify the occurrence of adverse effects 
of the GMO or its use on human health or the environment which were not anticipated in the 
environmental risk assessment. 
 
Post-market environmental monitoring is composed of case-specific monitoring and general 
surveillance (EFSA 2011c). Case-specific monitoring is not obligatory, but may be required to verify 
assumptions and conclusions of the ERA, whereas general surveillance is mandatory, in order to take 
account for general or unspecific scientific uncertainty and any unanticipated adverse effects 
associated with the release and management of a GM plant. Due to different objectives between case-
specific monitoring and general surveillance, their underlying concepts differ. Case-specific 
monitoring should enable the determination of whether and to what extent adverse effects anticipated 
in the environmental risk assessment occur during the commercial use of a GM plant, and thus to 
relate observed changes to specific risks. It is triggered by scientific uncertainty that was identified in 
the ERA. 
 
The objective of general surveillance is to identify unanticipated adverse effects of the GM plant or its 
use on human health and the environment that were not predicted or specifically identified during the 
ERA. In contrast to case-specific monitoring, the general status of the environment that is associated 
with the use of the GM plant is monitored without any preconceived hypothesis, in order to detect any 
possible effects that were not anticipated in the ERA, or that are long-term or cumulative.  
 
No specific environmental impact of genetically modified maize Bt11 was indicated by the 
environmental risk assessment and thus no case specific monitoring is required. The VKM GMO 
Panel is of the opinion that the scope of the monitoring plan provided by the applicant is in line with 
the intended uses of maize NK603 since the environmental risk assessment did not cover cultivation 
and identified no potential adverse environmental effects.  
 
5.7  Conclusion 
 
The scope of the application EFSA/GMO/RX/Bt11 includes import and processing of maize Bt11 for 
food and feed uses. Considering the intended uses of maize Bt11, excluding cultivation, the 
environmental risk assessment is concerned with accidential release into the environment of viable 
grains during transportation and processing, and indirect exposure, mainly through manure and faeces 
from animals fed grains from maize Bt11.  
 
Maize Bt11 has no altered survival, multiplication or dissemination characteristics, and there are no 
indications of an increased likelihood of spread and establishment of feral maize plants in the case of 
accidential release into the environment of seeds from maize Bt11. Maize is the only representative of 
the genus Zea in Europe, and there are no cross-compatible wild or weedy relatives outside 
cultivation. The risk of gene flow from occasional feral GM maize plants to conventional maize 
varieties is negligible. Considering the intended use as food and feed, interactions with the biotic and 
abiotic environment are not considered to be an issue. 
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6 Data gaps  
 
Adjuvanticity   
 
There are many knowledge gaps related to assessment of adjuvants. Most of the immunologic 
adjuvant experiments have been performed using Cry1Ac. Whether the other Cry proteins have similar 
adjuvant properties is unknown.  
 
The quantities of Cry proteins in genetically modified maize and soya are marginal compared with the 
amounts of other adjuvants that are natural components of food. However, the extent to which these 
naturally occurring adjuvants and Cry proteins contribute to the development of allergies is largely 
unknown. Determination of their importance is hampered by the lack of validated methods for 
measuring adjuvant effects.  
 
The possibility that Cry proteins might increase the permeability of the intestinal epithelium and 
thereby lead to "bystander" sensitization to strong allergens in the diet of genetically susceptible 
individuals cannot be completely excluded. This possibility could be explored in a relevant animal 
model.  
 
One element of uncertainty in exposure assessment is the lack of knowledge concerning exposure via 
the respiratory tract and the skin, and also the lack of quantitative understanding of the relationship 
between the extent of exposure to an adjuvant and its effects in terms of development of allergies. 
 
Herbicide residue levels  
Herbicide residue levels on plants with engineered resistance to one or two broad spectrum herbicides 
could entail higher levels of herbicide residue cocktails compared to plants produced by conventional 
farming practice. 
 
Since it is difficult to predict the toxicity of cocktails from the toxicity of the single components, there 
is uncertainty related to risk of confounding effects such as additive or synergistic effects between the 
residues in herbicide resistant plants.   
 
The transgene technology used can possibly lead to different metabolic products of the applied 
herbicides from what is expected from conventional usage. The risk assessment of herbicides 
should take into account plants with altered metabolism.  
 
At present the changes related to herbicide residues of stacked plants as a result of the application 

















Molecular characterisation  
The molecular characterisation data indicate that a single copy of the transgenic insert with the cry1Ab 
and pat genes is integrated  in the nuclear genome of maize Bt11, and that it is inherited as a dominant, 
single locus trait. Appropriate analyses of the integration site, inserted DNA sequence, flanking 
regions, and bioinformatics have been performed. The VKM GMO Panel considers the molecular 
characterisation of maize Bt11 as adequate. 
 
Comparative assessment 
Comparative analyses of data from field trials located at representative sites and environments in 
North America and Europe indicate that maize Bt11 is compositionally equivalent to its conventional 
counterpart, with the exception of the herbicide tolerance and insect resistance traits, conferred by the 
expression of the Cry1Ab and PAT proteins. However, data on the amino acid tryptophan, is only 
given in one out of six studies. Based on current knowledge, the VKM GMO panel concludes that 
maize Bt11 is compositionally equivalent to conventional maize. 
 
The data provided by the applicant are not sufficient to show that Bt11 maize is phenotypically and 
agronomically equivalent to conventional near-isogenic maize lines. The agronomic assessment data 
are provided from one growing season in the North America and one growing season in France. This 
is not considered to be sufficient for representative testing of agricultural environments. 
 
Food and feed risk assessment 
Whole food feeding studies have not indicated any adverse health effects of maize Bt11. These studies 
also indicate that maize Bt11 is nutritionally equivalent to conventional maize. The Cry1Ab and PAT 
proteins do not show sequence resemblance to other known toxins or IgE allergens, nor have they 
been reported to cause IgE mediated allergic reactions. Some studies have however indicated a 
potential role of Cry-proteins as adjuvants in allergic reactions. 
 
Based on current knowledge, the VKM GMO Panel concludes that maize Bt11 is nutritionally 
equivalent to conventional maize varieties. It is unlikely that the Cry1Ab and PAT proteins will 
introduce a toxic or allergenic potential in food or feed based on maize Bt11 compared to conventional 
maize. 
 
Environmental risk assessment 
The scope of the application EFSA/GMO/RX/Bt11 includes import and processing of maize Bt11 for 
food and feed uses. Considering the intended uses of maize Bt11, excluding cultivation, the 
environmental risk assessment is concerned with accifieldal release into the environment of viable 
grains during transportation and processing, and indirect exposure, mainly through manure and faeces 
from animals fed grains from maize Bt11.  
 
Maize Bt11 has no altered survival, multiplication or dissemination characteristics, and there are no 
indications of an increased likelihood of spread and establishment of feral maize plants in the case of 
accifieldal release into the environment of seeds from maize Bt11. Maize is the only representative of 
the genus Zea in Europe, and there are no cross-compatible wild or weedy relatives outside 
cultivation. The VKM GMO Panel considers the risk of gene flow from occasional feral GM maize 
plants to conventional maize varieties to be negligible in Norway. Considering the intended use as 
food and feed, interactions with the biotic and abiotic environment are not considered by the GMO 
Panel to be an issue. 
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Overall conclusion 
Based on current knowledge, the VKM GMO Panel concludes that maize Bt11 is nutritionally 
equivalent to conventional maize varieties. It is unlikely that the Cry1Ab and PAT proteins will 
introduce a toxic or allergenic potential in food or feed derived from maize Bt11 compared to 
conventional maize.  
 
The VKM GMO Panel likewise concludes that maize Bt11, based on current knowledge, is 
comparable to conventional maize varieties concerning environmental risk in Norway with the 
intended usage. 
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Table 1. Summary of lines evaluated (ANFZA 2000). 
 
